-
1
-
-
85013388313
-
Cancer Moonshot. Blue Ribbon Panel Report
-
(accessed Sept 30, 2017).
-
National Cancer Institute. Cancer Moonshot. Blue Ribbon Panel Report. https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel/blue-ribbon-panel-report-2016.pdf, 2016 (accessed Sept 30, 2017).
-
(2016)
-
-
-
2
-
-
84973467506
-
Aiming high—changing the trajectory for cancer
-
Lowy, DR, Collins, FS, Aiming high—changing the trajectory for cancer. N Engl J Med 374 (2016), 1901–1904.
-
(2016)
N Engl J Med
, vol.374
, pp. 1901-1904
-
-
Lowy, D.R.1
Collins, F.S.2
-
4
-
-
85015642839
-
Realizing the potential of cancer prevention—the role of implementation science
-
Emmons, KM, Colditz, GA, Realizing the potential of cancer prevention—the role of implementation science. N Engl J Med 376 (2017), 986–990.
-
(2017)
N Engl J Med
, vol.376
, pp. 986-990
-
-
Emmons, K.M.1
Colditz, G.A.2
-
5
-
-
85029706147
-
Physical activity, sedentary behavior, diet, and cancer: an update and emerging new evidence
-
Kerr, J, Anderson, CA, Lippman, SM, Physical activity, sedentary behavior, diet, and cancer: an update and emerging new evidence. Lancet Oncol 18 (2017), e457–e471.
-
(2017)
Lancet Oncol
, vol.18
, pp. e457-e471
-
-
Kerr, J.1
Anderson, C.A.2
Lippman, S.M.3
-
6
-
-
85016324008
-
Interaction landscape of inherited polymorphisms with somatic events in cancer
-
Carter, H, Marty, R, Hofree, M, et al. Interaction landscape of inherited polymorphisms with somatic events in cancer. Cancer Discov 7 (2017), 410–423.
-
(2017)
Cancer Discov
, vol.7
, pp. 410-423
-
-
Carter, H.1
Marty, R.2
Hofree, M.3
-
7
-
-
84969965544
-
Association of leisure–time physical activity with risk of 26 types of cancer in 1.44 million adults
-
Moore, SC, Lee, IM, Weiderpass, E, et al. Association of leisure–time physical activity with risk of 26 types of cancer in 1.44 million adults. JAMA Intern Med 176 (2016), 816–825.
-
(2016)
JAMA Intern Med
, vol.176
, pp. 816-825
-
-
Moore, S.C.1
Lee, I.M.2
Weiderpass, E.3
-
8
-
-
84960099239
-
The impact of physical activity on health–related fitness and quality of life for patients with head and neck cancer: a systematic review
-
Capozzi, LC, Nishimura, KC, McNeely, ML, Lau, H, Culos–Reed, SN, The impact of physical activity on health–related fitness and quality of life for patients with head and neck cancer: a systematic review. Br J Sports Med 50 (2016), 325–338.
-
(2016)
Br J Sports Med
, vol.50
, pp. 325-338
-
-
Capozzi, L.C.1
Nishimura, K.C.2
McNeely, M.L.3
Lau, H.4
Culos-Reed, S.N.5
-
9
-
-
85001950460
-
Occupational sedentariness and breast cancer risk
-
Johnsson, A, Broberg, P, Johnsson, A, Tornberg, AB, Olsson, H, Occupational sedentariness and breast cancer risk. Acta Oncol 56 (2017), 75–80.
-
(2017)
Acta Oncol
, vol.56
, pp. 75-80
-
-
Johnsson, A.1
Broberg, P.2
Johnsson, A.3
Tornberg, A.B.4
Olsson, H.5
-
10
-
-
84979734815
-
Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women
-
Ekelund, U, Steene-Johannessen, J, Brown, WJ, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women. Lancet 388 (2016), 1302–1310.
-
(2016)
Lancet
, vol.388
, pp. 1302-1310
-
-
Ekelund, U.1
Steene-Johannessen, J.2
Brown, W.J.3
-
11
-
-
85017497120
-
Impact of Mediterranean diet on metabolic syndrome, cancer and longevity
-
Di Daniele, N, Noce, A, Vidiri, MF, et al. Impact of Mediterranean diet on metabolic syndrome, cancer and longevity. Oncotarget 8 (2017), 8947–8979.
-
(2017)
Oncotarget
, vol.8
, pp. 8947-8979
-
-
Di Daniele, N.1
Noce, A.2
Vidiri, M.F.3
-
12
-
-
23744506376
-
Intensive lifestyle changes may affect the progression of prostate cancer
-
Ornish, D, Weidner, G, Fair, WR, et al. Intensive lifestyle changes may affect the progression of prostate cancer. J Urol 174 (2005), 1065–1070.
-
(2005)
J Urol
, vol.174
, pp. 1065-1070
-
-
Ornish, D.1
Weidner, G.2
Fair, W.R.3
-
13
-
-
54349098423
-
Increased telomerase activity and comprehensive lifestyle changes: a pilot study
-
Ornish, D, Lin, J, Daubenmier, J, et al. Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol 9 (2008), 1048–1057.
-
(2008)
Lancet Oncol
, vol.9
, pp. 1048-1057
-
-
Ornish, D.1
Lin, J.2
Daubenmier, J.3
-
14
-
-
84884700070
-
Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study
-
Ornish, D, Lin, J, Chan, JM, et al. Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol 14 (2013), 1112–1120.
-
(2013)
Lancet Oncol
, vol.14
, pp. 1112-1120
-
-
Ornish, D.1
Lin, J.2
Chan, J.M.3
-
15
-
-
0032539162
-
Intensive lifestyle changes for reversal of coronary heart disease
-
Ornish, D, Scherwitz, LW, Billings, JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280 (1998), 2001–2007.
-
(1998)
JAMA
, vol.280
, pp. 2001-2007
-
-
Ornish, D.1
Scherwitz, L.W.2
Billings, J.H.3
-
16
-
-
0037034257
-
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
-
Knowler, WC, Barrett-Connor, E, Fowler, SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002), 393–403.
-
(2002)
N Engl J Med
, vol.346
, pp. 393-403
-
-
Knowler, W.C.1
Barrett-Connor, E.2
Fowler, S.E.3
-
17
-
-
77955845440
-
The power of exercise: buffering the effect of chronic stress on telomere length
-
Puterman, E, Lin, J, Blackburn, E, O'Donovan, A, Adler, N, Epel, E, The power of exercise: buffering the effect of chronic stress on telomere length. PLoS One, 5, 2010, e10837.
-
(2010)
PLoS One
, vol.5
, pp. e10837
-
-
Puterman, E.1
Lin, J.2
Blackburn, E.3
O'Donovan, A.4
Adler, N.5
Epel, E.6
-
18
-
-
84941774531
-
Dietary patterns after prostate cancer diagnosis in relation to disease-specific and total mortality
-
Yang, M, Kenfield, SA, Van Blarigan, EL, et al. Dietary patterns after prostate cancer diagnosis in relation to disease-specific and total mortality. Cancer Prev Res 8 (2015), 545–551.
-
(2015)
Cancer Prev Res
, vol.8
, pp. 545-551
-
-
Yang, M.1
Kenfield, S.A.2
Van Blarigan, E.L.3
-
19
-
-
84953897523
-
Vegetable and fruit consumption and the risk of hormone receptor-defined breast cancer in the EPIC cohort
-
Emaus, MJ, Peeters, PH, Bakker, MF, et al. Vegetable and fruit consumption and the risk of hormone receptor-defined breast cancer in the EPIC cohort. Am J Clin Nutr 103 (2016), 168–177.
-
(2016)
Am J Clin Nutr
, vol.103
, pp. 168-177
-
-
Emaus, M.J.1
Peeters, P.H.2
Bakker, M.F.3
-
20
-
-
84873600352
-
Fruit and vegetable intake and risk of breast cancer by hormone receptor status
-
Jung, S, Spiegelman, D, Baglietto, L, et al. Fruit and vegetable intake and risk of breast cancer by hormone receptor status. J Natl Cancer Inst 105 (2013), 219–236.
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 219-236
-
-
Jung, S.1
Spiegelman, D.2
Baglietto, L.3
-
21
-
-
84969808380
-
Fruit and vegetable consumption in adolescence and early adulthood and risk of breast cancer: population based cohort study
-
Farvid, MS, Chen, WY, Michels, KB, Cho, E, Willett, WC, Eliassen, AH, Fruit and vegetable consumption in adolescence and early adulthood and risk of breast cancer: population based cohort study. BMJ, 353, 2016, i2343.
-
(2016)
BMJ
, vol.353
, pp. i2343
-
-
Farvid, M.S.1
Chen, W.Y.2
Michels, K.B.3
Cho, E.4
Willett, W.C.5
Eliassen, A.H.6
-
22
-
-
84946147457
-
Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the PREDIMED trial: a randomized clinical trial
-
Toledo, E, Salas-Salvado, J, Donat-Vargas, C, et al. Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the PREDIMED trial: a randomized clinical trial. JAMA Intern Med 175 (2015), 1752–1760.
-
(2015)
JAMA Intern Med
, vol.175
, pp. 1752-1760
-
-
Toledo, E.1
Salas-Salvado, J.2
Donat-Vargas, C.3
-
23
-
-
84958225366
-
The macrophage switch in obesity development
-
Castoldi, A, Naffah de Souza, C, Camara, NO, Moraes-Vieira, PM, The macrophage switch in obesity development. Front Immunol, 6, 2015, 637.
-
(2015)
Front Immunol
, vol.6
, pp. 637
-
-
Castoldi, A.1
Naffah de Souza, C.2
Camara, N.O.3
Moraes-Vieira, P.M.4
-
24
-
-
84895727751
-
Low protein intake is associated with a major reduction in IGF–1, cancer, and overall mortality in the 65 and younger but not older population
-
Levine, ME, Suarez, JA, Brandhorst, S, et al. Low protein intake is associated with a major reduction in IGF–1, cancer, and overall mortality in the 65 and younger but not older population. Cell Metab 19 (2014), 407–417.
-
(2014)
Cell Metab
, vol.19
, pp. 407-417
-
-
Levine, M.E.1
Suarez, J.A.2
Brandhorst, S.3
-
25
-
-
84920895872
-
A red meat-derived glycan promotes inflammation and cancer progression
-
Samraj, AN, Pearce, OM, Laubli, H, et al. A red meat-derived glycan promotes inflammation and cancer progression. Proc Natl Acad Sci USA 112 (2015), 542–547.
-
(2015)
Proc Natl Acad Sci USA
, vol.112
, pp. 542-547
-
-
Samraj, A.N.1
Pearce, O.M.2
Laubli, H.3
-
26
-
-
84978115999
-
The microbiome and innate immunity
-
Thaiss, CA, Zmora, N, Levy, M, Elinav, E, The microbiome and innate immunity. Nature 535 (2016), 65–74.
-
(2016)
Nature
, vol.535
, pp. 65-74
-
-
Thaiss, C.A.1
Zmora, N.2
Levy, M.3
Elinav, E.4
-
27
-
-
85017381640
-
Association of dietary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue
-
Mehta, RS, Nishihara, R, Cao, Y, et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue. JAMA Oncol 3 (2017), 921–927.
-
(2017)
JAMA Oncol
, vol.3
, pp. 921-927
-
-
Mehta, R.S.1
Nishihara, R.2
Cao, Y.3
-
28
-
-
84885634549
-
Metabolic syndrome: F stands for fructose and fat
-
Lyssiotis, CA, Cantley, LC, Metabolic syndrome: F stands for fructose and fat. Nature 502 (2013), 181–182.
-
(2013)
Nature
, vol.502
, pp. 181-182
-
-
Lyssiotis, C.A.1
Cantley, L.C.2
-
29
-
-
84942792026
-
Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk
-
Murphy, EA, Velazquez, KT, Herbert, KM, Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk. Curr Opin Clin Nutr Metab Care 18 (2015), 515–520.
-
(2015)
Curr Opin Clin Nutr Metab Care
, vol.18
, pp. 515-520
-
-
Murphy, E.A.1
Velazquez, K.T.2
Herbert, K.M.3
-
30
-
-
85017373900
-
Gut microbiota promotes obesity–associated liver cancer through pge2–mediated suppression of antitumor immunity
-
Loo, TM, Kamachi, F, Watanabe, Y, et al. Gut microbiota promotes obesity–associated liver cancer through pge2–mediated suppression of antitumor immunity. Cancer Discov 7 (2017), 522–538.
-
(2017)
Cancer Discov
, vol.7
, pp. 522-538
-
-
Loo, T.M.1
Kamachi, F.2
Watanabe, Y.3
-
31
-
-
85004115511
-
Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis
-
Kettner, NM, Voicu, H, Finegold, MJ, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell 30 (2016), 909–924.
-
(2016)
Cancer Cell
, vol.30
, pp. 909-924
-
-
Kettner, N.M.1
Voicu, H.2
Finegold, M.J.3
-
32
-
-
84929266699
-
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
-
Neuschwander-Tetri, BA, Loomba, R, Sanyal, AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
-
(2015)
Lancet
, vol.385
, pp. 956-965
-
-
Neuschwander-Tetri, B.A.1
Loomba, R.2
Sanyal, A.J.3
-
33
-
-
84987802495
-
Erlotinib and the risk of oral cancer: the Erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial
-
William, WN Jr, Papadimitrakopoulou, V, Lee, JJ, et al. Erlotinib and the risk of oral cancer: the Erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial. JAMA Oncol 2 (2016), 209–216.
-
(2016)
JAMA Oncol
, vol.2
, pp. 209-216
-
-
William, W.N.1
Papadimitrakopoulou, V.2
Lee, J.J.3
-
34
-
-
84976582488
-
Oral cancer chemoprevention–the end of EPOC, the beginning of an epoch of molecular selection
-
Bauman, JE, Grandis, J, Oral cancer chemoprevention–the end of EPOC, the beginning of an epoch of molecular selection. JAMA Oncol 2 (2016), 178–179.
-
(2016)
JAMA Oncol
, vol.2
, pp. 178-179
-
-
Bauman, J.E.1
Grandis, J.2
-
35
-
-
84982766646
-
Immune-modulation by epidermal growth factor receptor inhibitors: implication on anti–tumor immunity in lung cancer
-
Im, JS, Herrmann, AC, Bernatchez, C, et al. Immune-modulation by epidermal growth factor receptor inhibitors: implication on anti–tumor immunity in lung cancer. PLoS One, 11, 2016, e0160004.
-
(2016)
PLoS One
, vol.11
, pp. e0160004
-
-
Im, J.S.1
Herrmann, A.C.2
Bernatchez, C.3
-
36
-
-
85036497908
-
Immune profiling of oral pre-malignant lesions (OPLs): an Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis
-
William, WN Jr, Uraoka, N, Peng, SA, et al. Immune profiling of oral pre-malignant lesions (OPLs): an Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis. J Clin Oncol, 35(suppl), 2017, 1545.
-
(2017)
J Clin Oncol
, vol.35
, pp. 1545
-
-
William, W.N.1
Uraoka, N.2
Peng, S.A.3
-
37
-
-
85010679719
-
Population-wide impact of long-term use of aspirin and the risk for cancer
-
Cao, Y, Nishihara, R, Wu, K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol 2 (2016), 762–769.
-
(2016)
JAMA Oncol
, vol.2
, pp. 762-769
-
-
Cao, Y.1
Nishihara, R.2
Wu, K.3
-
38
-
-
84959516180
-
Aspirin and colorectal cancer: the promise of precision chemoprevention
-
Drew, DA, Cao, Y, Chan, AT, Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 16 (2016), 173–186.
-
(2016)
Nat Rev Cancer
, vol.16
, pp. 173-186
-
-
Drew, D.A.1
Cao, Y.2
Chan, A.T.3
-
39
-
-
84952660923
-
Where do we stand with aspirin for the prevention of colorectal cancer? The USPSTF recommendations
-
Chan, AT, Ladabaum, U, Where do we stand with aspirin for the prevention of colorectal cancer? The USPSTF recommendations. Gastroenterology 150 (2016), 14–18.
-
(2016)
Gastroenterology
, vol.150
, pp. 14-18
-
-
Chan, A.T.1
Ladabaum, U.2
-
40
-
-
84899547782
-
Aspirin and the risk of colorectal cancer in relation to the expression of 15–hydroxyprostaglandin dehydrogenase (HPGD)
-
Fink, SP, Yamauchi, M, Nishihara, R, et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15–hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med, 6, 2014, 233re2.
-
(2014)
Sci Transl Med
, vol.6
, pp. 233re2
-
-
Fink, S.P.1
Yamauchi, M.2
Nishihara, R.3
-
41
-
-
84892607343
-
Realizing the promise of cancer predisposition genes
-
Rahman, N, Realizing the promise of cancer predisposition genes. Nature 505 (2014), 302–308.
-
(2014)
Nature
, vol.505
, pp. 302-308
-
-
Rahman, N.1
-
42
-
-
84904354146
-
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in Brca1–deficient mice
-
To, C, Kim, EH, Royce, DB, et al. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in Brca1–deficient mice. Cancer Prev Res (Phila) 7 (2014), 698–707.
-
(2014)
Cancer Prev Res (Phila)
, vol.7
, pp. 698-707
-
-
To, C.1
Kim, E.H.2
Royce, D.B.3
-
43
-
-
84964398060
-
Microsatellite instability as a biomarker for PD–1 blockade
-
Dudley, JC, Lin, MT, Le, DT, Eshleman, JR, Microsatellite instability as a biomarker for PD–1 blockade. Clin Cancer Res 22 (2016), 813–820.
-
(2016)
Clin Cancer Res
, vol.22
, pp. 813-820
-
-
Dudley, J.C.1
Lin, M.T.2
Le, D.T.3
Eshleman, J.R.4
-
44
-
-
84932628341
-
PD–1 blockade in tumors with mismatch-repair deficiency
-
Le, DT, Uram, JN, Wang, H, et al. PD–1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
-
(2015)
N Engl J Med
, vol.372
, pp. 2509-2520
-
-
Le, D.T.1
Uram, J.N.2
Wang, H.3
-
45
-
-
84944898663
-
A phase 3 randomized trial of nicotinamide for skin–cancer chemoprevention
-
Chen, AC, Martin, AJ, Choy, B, et al. A phase 3 randomized trial of nicotinamide for skin–cancer chemoprevention. N Engl J Med 373 (2015), 1618–1626.
-
(2015)
N Engl J Med
, vol.373
, pp. 1618-1626
-
-
Chen, A.C.1
Martin, A.J.2
Choy, B.3
-
46
-
-
84962327352
-
Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial
-
Samadder, NJ, Neklason, DW, Boucher, KM, et al. Effect of sulindac and erlotinib vs placebo on duodenal neoplasia in familial adenomatous polyposis: a randomized clinical trial. JAMA 315 (2016), 1266–1275.
-
(2016)
JAMA
, vol.315
, pp. 1266-1275
-
-
Samadder, N.J.1
Neklason, D.W.2
Boucher, K.M.3
-
47
-
-
84959307535
-
Clonal immunoglobulin against lysolipids in the origin of myeloma
-
Nair, S, Branagan, AR, Liu, J, Boddupalli, CS, Mistry, PK, Dhodapkar, MV, Clonal immunoglobulin against lysolipids in the origin of myeloma. N Engl J Med 374 (2016), 555–561.
-
(2016)
N Engl J Med
, vol.374
, pp. 555-561
-
-
Nair, S.1
Branagan, A.R.2
Liu, J.3
Boddupalli, C.S.4
Mistry, P.K.5
Dhodapkar, M.V.6
-
48
-
-
85015636587
-
MGUS to myeloma: a mysterious gammopathy of underexplored significance
-
Dhodapkar, MV, MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 128 (2016), 2599–2606.
-
(2016)
Blood
, vol.128
, pp. 2599-2606
-
-
Dhodapkar, M.V.1
-
49
-
-
85018592899
-
Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer
-
Pearlman, R, Frankel, WL, Swanson, B, et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3 (2017), 464–471.
-
(2017)
JAMA Oncol
, vol.3
, pp. 464-471
-
-
Pearlman, R.1
Frankel, W.L.2
Swanson, B.3
-
50
-
-
84951293785
-
Patterns and functional implications of rare germline variants across 12 cancer types
-
Lu, C, Xie, M, Wendl, MC, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun, 6, 2015, 10086.
-
(2015)
Nat Commun
, vol.6
, pp. 10086
-
-
Lu, C.1
Xie, M.2
Wendl, M.C.3
-
51
-
-
84984760593
-
Somatic and germline genetics at the JAK2 locus
-
Campbell, PJ, Somatic and germline genetics at the JAK2 locus. Nat Genet 41 (2009), 385–386.
-
(2009)
Nat Genet
, vol.41
, pp. 385-386
-
-
Campbell, P.J.1
-
52
-
-
79953302806
-
Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions
-
Liu, W, He, L, Ramirez, J, et al. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res 71 (2011), 2423–2427.
-
(2011)
Cancer Res
, vol.71
, pp. 2423-2427
-
-
Liu, W.1
He, L.2
Ramirez, J.3
-
53
-
-
85016626649
-
Cancer susceptibility gene mutations in individuals with colorectal cancer
-
Yurgelun, MB, Kulke, MH, Fuchs, CS, et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 35 (2017), 1086–1095.
-
(2017)
J Clin Oncol
, vol.35
, pp. 1086-1095
-
-
Yurgelun, M.B.1
Kulke, M.H.2
Fuchs, C.S.3
-
54
-
-
85012118567
-
Translating germline cancer risk into precision prevention
-
Yurgelun, MB, Chenevix-Trench, G, Lippman, SM, Translating germline cancer risk into precision prevention. Cell 168 (2017), 566–570.
-
(2017)
Cell
, vol.168
, pp. 566-570
-
-
Yurgelun, M.B.1
Chenevix-Trench, G.2
Lippman, S.M.3
-
55
-
-
84975295506
-
RANK ligand as a potential target for breast cancer prevention in BRCA1–mutation carriers
-
Nolan, E, Vaillant, F, Branstetter, D, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1–mutation carriers. Nat Med 22 (2016), 933–939.
-
(2016)
Nat Med
, vol.22
, pp. 933-939
-
-
Nolan, E.1
Vaillant, F.2
Branstetter, D.3
-
56
-
-
84971659586
-
Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long–term prospective follow-up studies from three European expert centers
-
Vasen, H, Ibrahim, I, Ponce, CG, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long–term prospective follow-up studies from three European expert centers. J Clin Oncol 34 (2016), 2010–2019.
-
(2016)
J Clin Oncol
, vol.34
, pp. 2010-2019
-
-
Vasen, H.1
Ibrahim, I.2
Ponce, C.G.3
-
57
-
-
85012982843
-
Risk stratification of Barrett's oesophagus using a non–endoscopic sampling method coupled with a biomarker panel: a cohort study
-
Ross-Innes, CS, Chettouh, H, Achilleos, A, et al. Risk stratification of Barrett's oesophagus using a non–endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol 2 (2017), 23–31.
-
(2017)
Lancet Gastroenterol Hepatol
, vol.2
, pp. 23-31
-
-
Ross-Innes, C.S.1
Chettouh, H.2
Achilleos, A.3
-
58
-
-
84875490185
-
Cancer genome landscapes
-
Vogelstein, B, Papadopoulos, N, Velculescu, VE, Zhou, S, Diaz, LA Jr, Kinzler, KW, Cancer genome landscapes. Science 339 (2013), 1546–1558.
-
(2013)
Science
, vol.339
, pp. 1546-1558
-
-
Vogelstein, B.1
Papadopoulos, N.2
Velculescu, V.E.3
Zhou, S.4
Diaz, L.A.5
Kinzler, K.W.6
-
59
-
-
84973164097
-
Genomic landscape of colorectal mucosa and adenomas
-
Borras, E, San Lucas, FA, Chang, K, et al. Genomic landscape of colorectal mucosa and adenomas. Cancer Prev Res (Phila) 9 (2016), 417–427.
-
(2016)
Cancer Prev Res (Phila)
, vol.9
, pp. 417-427
-
-
Borras, E.1
San Lucas, F.A.2
Chang, K.3
-
60
-
-
85009470013
-
Insertions and deletions target lineage-defining genes in human cancers
-
Imielinski, M, Guo, G, Meyerson, M, Insertions and deletions target lineage-defining genes in human cancers. Cell 168 (2017), 460–472.
-
(2017)
Cell
, vol.168
, pp. 460-472
-
-
Imielinski, M.1
Guo, G.2
Meyerson, M.3
-
61
-
-
85012921656
-
Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia
-
Kotini, AG, Chang, CJ, Chow, A, et al. Stage-specific human induced pluripotent stem cells map the progression of myeloid transformation to transplantable leukemia. Cell Stem Cell 20 (2017), 315–328.
-
(2017)
Cell Stem Cell
, vol.20
, pp. 315-328
-
-
Kotini, A.G.1
Chang, C.J.2
Chow, A.3
-
62
-
-
85009113270
-
A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation
-
Nestorowa, S, Hamey, FK, Pijuan Sala, B, et al. A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. Blood 128 (2016), e20–e31.
-
(2016)
Blood
, vol.128
, pp. e20-e31
-
-
Nestorowa, S.1
Hamey, F.K.2
Pijuan Sala, B.3
-
63
-
-
84958729616
-
A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation
-
Kaufman, CK, Mosimann, C, Fan, ZP, et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science, 351, 2016, aad2197.
-
(2016)
Science
, vol.351
, pp. aad2197
-
-
Kaufman, C.K.1
Mosimann, C.2
Fan, Z.P.3
-
64
-
-
85018823113
-
Childhood cancers
-
H Gelband P Jha R Sankaranaryanan S Horton 3rd edn. World Bank Washington, DC
-
Gupta, S, Howard, SC, Hunger, SP, et al. Childhood cancers. Gelband, H, Jha, P, Sankaranaryanan, R, Horton, S, (eds.) Disease control priorities, 3rd edn., 2015, World Bank, Washington, DC.
-
(2015)
Disease control priorities
-
-
Gupta, S.1
Howard, S.C.2
Hunger, S.P.3
-
65
-
-
84964004871
-
New costly cancer treatments face hurdles getting to patients
-
(accessed May 9, 2017).
-
Plumridge, H, New costly cancer treatments face hurdles getting to patients. Wall Street Journal, Oct 6, 2014 https://www.wsj.com/articles/new-costly-cancer-treatments-face-hurdles-getting-to-patients-1412627150 (accessed May 9, 2017).
-
(2014)
Wall Street Journal
-
-
Plumridge, H.1
-
66
-
-
84916218648
-
Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer
-
Yoda, Y, Takeshima, H, Niwa, T, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer 18 (2015), 65–76.
-
(2015)
Gastric Cancer
, vol.18
, pp. 65-76
-
-
Yoda, Y.1
Takeshima, H.2
Niwa, T.3
-
67
-
-
85011306580
-
Not all H3K4 methylations are created equal: Mll2/COMPASS dependency in primordial germ cell specification
-
Hu, D, Gao, X, Cao, K, et al. Not all H3K4 methylations are created equal: Mll2/COMPASS dependency in primordial germ cell specification. Mol Cell 65 (2017), 460–475.
-
(2017)
Mol Cell
, vol.65
, pp. 460-475
-
-
Hu, D.1
Gao, X.2
Cao, K.3
-
68
-
-
84983233354
-
Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus
-
Martinez, P, Timmer, MR, Lau, CT, et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett's oesophagus. Nat Commun, 7, 2016, 12158.
-
(2016)
Nat Commun
, vol.7
, pp. 12158
-
-
Martinez, P.1
Timmer, M.R.2
Lau, C.T.3
-
69
-
-
84863229772
-
Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm
-
Hou, Y, Song, L, Zhu, P, et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 148 (2012), 873–885.
-
(2012)
Cell
, vol.148
, pp. 873-885
-
-
Hou, Y.1
Song, L.2
Zhu, P.3
-
70
-
-
85017360311
-
Scaling single-cell genomics from phenomenology to mechanism
-
Tanay, A, Regev, A, Scaling single-cell genomics from phenomenology to mechanism. Nature 541 (2017), 331–338.
-
(2017)
Nature
, vol.541
, pp. 331-338
-
-
Tanay, A.1
Regev, A.2
-
71
-
-
0037648348
-
The case for early detection
-
Etzioni, R, Urban, N, Ramsey, S, et al. The case for early detection. Nat Rev Cancer 3 (2003), 243–252.
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 243-252
-
-
Etzioni, R.1
Urban, N.2
Ramsey, S.3
-
72
-
-
84960799406
-
Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening
-
Smith, RA, Andrews, K, Brooks, D, et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 66 (2016), 95–114.
-
(2016)
CA Cancer J Clin
, vol.66
, pp. 95-114
-
-
Smith, R.A.1
Andrews, K.2
Brooks, D.3
-
73
-
-
85020082265
-
Universal genetic testing for younger patients with colorectal cancer
-
Vilar, E, Stoffel, EM, Universal genetic testing for younger patients with colorectal cancer. JAMA Oncol 3 (2016), 448–449.
-
(2016)
JAMA Oncol
, vol.3
, pp. 448-449
-
-
Vilar, E.1
Stoffel, E.M.2
-
74
-
-
70350608273
-
A community effort to reduce the black/white breast cancer mortality disparity in Chicago
-
Ansell, D, Grabler, P, Whitman, S, et al. A community effort to reduce the black/white breast cancer mortality disparity in Chicago. Cancer Caus Control 20 (2009), 1681–1688.
-
(2009)
Cancer Caus Control
, vol.20
, pp. 1681-1688
-
-
Ansell, D.1
Grabler, P.2
Whitman, S.3
-
75
-
-
84866562681
-
Regular screening mammography before the diagnosis of breast cancer reduces black:white breast cancer differences and modifies negative biological prognostic factors
-
Grabler, P, Dupuy, D, Rai, J, Bernstein, S, Ansell, D, Regular screening mammography before the diagnosis of breast cancer reduces black:white breast cancer differences and modifies negative biological prognostic factors. Breast Cancer Res Treat 135 (2012), 549–553.
-
(2012)
Breast Cancer Res Treat
, vol.135
, pp. 549-553
-
-
Grabler, P.1
Dupuy, D.2
Rai, J.3
Bernstein, S.4
Ansell, D.5
-
77
-
-
70349939381
-
decreased incidence of hepatocellular carcinoma in hepatitis b vaccinees: a 20-year follow-up study
-
Chang, M-H, You, S-L, Chen, C-J, et al., the Taiwan Hepatoma Study Group. decreased incidence of hepatocellular carcinoma in hepatitis b vaccinees: a 20-year follow-up study. J Natl Cancer Inst 101 (2009), 1348–1355.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 1348-1355
-
-
Chang, M.-H.1
You, S.-L.2
Chen, C.-J.3
-
78
-
-
84862750557
-
Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement
-
Moyer, VA, Force, USPST, Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156 (2012), 880–891.
-
(2012)
Ann Intern Med
, vol.156
, pp. 880-891
-
-
Moyer, V.A.1
Force, U.2
-
79
-
-
80053517807
-
Cancer prevention after cancer: changing the paradigm—a report from the American Society of Preventive Oncology
-
Campo, RA, Rowland, JH, Irwin, ML, Nathan, PC, Gritz, ER, Kinney, AY, Cancer prevention after cancer: changing the paradigm—a report from the American Society of Preventive Oncology. Cancer Epidemiol Biomarkers Prev 20 (2011), 2317–2324.
-
(2011)
Cancer Epidemiol Biomarkers Prev
, vol.20
, pp. 2317-2324
-
-
Campo, R.A.1
Rowland, J.H.2
Irwin, M.L.3
Nathan, P.C.4
Gritz, E.R.5
Kinney, A.Y.6
-
80
-
-
84973649618
-
Cancer treatment and survivorship statistics, 2016
-
Miller, KD, Siegel, RL, Lin, CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66 (2016), 271–289.
-
(2016)
CA Cancer J Clin
, vol.66
, pp. 271-289
-
-
Miller, K.D.1
Siegel, R.L.2
Lin, C.C.3
-
81
-
-
85051765476
-
Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008
-
Donin, N, Filson, C, Drakaki, A, et al. Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008. Cancer 122 (2016), 3075–3086.
-
(2016)
Cancer
, vol.122
, pp. 3075-3086
-
-
Donin, N.1
Filson, C.2
Drakaki, A.3
-
82
-
-
24944584561
-
A teachable moment for oncologists: cancer survivors, 10 million strong and growing!
-
Ganz, PA, A teachable moment for oncologists: cancer survivors, 10 million strong and growing!. J Clin Oncol 23 (2005), 5458–5460.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5458-5460
-
-
Ganz, P.A.1
-
83
-
-
33746990050
-
-
The National Academies Press Washington, DC
-
Hewitt, M, Greenfield, S, Stovall, E, From cancer patient to cancer survivor: lost in transition, 2006, The National Academies Press, Washington, DC.
-
(2006)
From cancer patient to cancer survivor: lost in transition
-
-
Hewitt, M.1
Greenfield, S.2
Stovall, E.3
-
84
-
-
77957949436
-
Rapid-learning system for cancer care
-
Abernethy, AP, Etheredge, LM, Ganz, PA, et al. Rapid-learning system for cancer care. J Clin Oncol 28 (2010), 4268–4274.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4268-4274
-
-
Abernethy, A.P.1
Etheredge, L.M.2
Ganz, P.A.3
-
85
-
-
84880653943
-
eliminating racial disparities in colorectal cancer in the real world: it took a village
-
Grubbs, SS, Polite, BN, Carney, J, et al. eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol 31 (2013), 1928–1930.
-
(2013)
J Clin Oncol
, vol.31
, pp. 1928-1930
-
-
Grubbs, S.S.1
Polite, B.N.2
Carney, J.3
-
86
-
-
85027437072
-
Leveraging implementation science to improve cancer care delivery and patient outcomes
-
Mitchell, SA, Chambers, DA, Leveraging implementation science to improve cancer care delivery and patient outcomes. J Oncol Pract 13 (2017), 523–529.
-
(2017)
J Oncol Pract
, vol.13
, pp. 523-529
-
-
Mitchell, S.A.1
Chambers, D.A.2
-
87
-
-
85011955335
-
How much longer will we put up with $100,000 cancer drugs?
-
Workman, P, Draetta, GF, Schellens, JH, Bernards, R, How much longer will we put up with $100,000 cancer drugs?. Cell 168 (2017), 579–583.
-
(2017)
Cell
, vol.168
, pp. 579-583
-
-
Workman, P.1
Draetta, G.F.2
Schellens, J.H.3
Bernards, R.4
-
88
-
-
85021105020
-
Clinical benefit, price and approval characteristics of FDA–approved new drugs for treating advanced solid cancer, 2000–2015
-
Vivot, A, Jacot, J, Zeitoun, JD, Ravaud, P, Crequit, P, Porcher, R, Clinical benefit, price and approval characteristics of FDA–approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol 28 (2017), 1111–1116.
-
(2017)
Ann Oncol
, vol.28
, pp. 1111-1116
-
-
Vivot, A.1
Jacot, J.2
Zeitoun, J.D.3
Ravaud, P.4
Crequit, P.5
Porcher, R.6
-
89
-
-
84959128138
-
Innovation in the pharmaceutical industry: New estimates of R&D costs
-
DiMasi, JA, Grabowski, HG, Hansen, RW, Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ 47 (2016), 20–33.
-
(2016)
J Health Econ
, vol.47
, pp. 20-33
-
-
DiMasi, J.A.1
Grabowski, H.G.2
Hansen, R.W.3
-
90
-
-
84892370974
-
Biomedical research: increasing value, reducing waste
-
Macleod, MR, Michie, S, Roberts, et al. Biomedical research: increasing value, reducing waste. Lancet 383 (2014), 101–104.
-
(2014)
Lancet
, vol.383
, pp. 101-104
-
-
Macleod, M.R.1
Michie, S.2
Roberts3
-
91
-
-
84859169880
-
Drug development: raise standards for preclinical cancer research
-
Begley, CG, Ellis, LM, Drug development: raise standards for preclinical cancer research. Nature 483 (2012), 531–533.
-
(2012)
Nature
, vol.483
, pp. 531-533
-
-
Begley, C.G.1
Ellis, L.M.2
-
92
-
-
85012110528
-
Clonal heterogeneity and tumor evolution: past, present, and the future
-
McGranahan, N, Swanton, C, Clonal heterogeneity and tumor evolution: past, present, and the future. Cell 168 (2017), 613–628.
-
(2017)
Cell
, vol.168
, pp. 613-628
-
-
McGranahan, N.1
Swanton, C.2
-
93
-
-
84998678876
-
Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review
-
Jardim, DL, Groves, ES, Breitfeld, PP, Kurzrock, R, Factors associated with failure of oncology drugs in late-stage clinical development: a systematic review. Cancer Treat Rev 52 (2017), 12–21.
-
(2017)
Cancer Treat Rev
, vol.52
, pp. 12-21
-
-
Jardim, D.L.1
Groves, E.S.2
Breitfeld, P.P.3
Kurzrock, R.4
-
94
-
-
85050577464
-
Academic drug discovery centers adapt to shifts in funding sources. Universities are pushing their novel molecules into clinical trials
-
Jarvis, LM, Academic drug discovery centers adapt to shifts in funding sources. Universities are pushing their novel molecules into clinical trials. Chemical Engineering News 95 (2017), 16–18.
-
(2017)
Chemical Engineering News
, vol.95
, pp. 16-18
-
-
Jarvis, L.M.1
-
95
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
Vogel, CL, Cobleigh, MA, Tripathy, D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (2002), 719–726.
-
(2002)
J Clin Oncol
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
-
96
-
-
55549101623
-
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
-
Ley, TJ, Mardis, ER, Ding, L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 (2008), 66–72.
-
(2008)
Nature
, vol.456
, pp. 66-72
-
-
Ley, T.J.1
Mardis, E.R.2
Ding, L.3
-
97
-
-
84928770388
-
Neoantigens in cancer immunotherapy
-
Schumacher, TN, Schreiber, RD, Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
-
(2015)
Science
, vol.348
, pp. 69-74
-
-
Schumacher, T.N.1
Schreiber, R.D.2
-
98
-
-
84963621254
-
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
-
Topalian, SL, Taube, JM, Anders, RA, Pardoll, DM, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 16 (2016), 275–287.
-
(2016)
Nat Rev Cancer
, vol.16
, pp. 275-287
-
-
Topalian, S.L.1
Taube, J.M.2
Anders, R.A.3
Pardoll, D.M.4
-
99
-
-
84990046448
-
Interleukin–10: an immune–activating cytokine in cancer immunotherapy
-
Zhang, H, Wang, Y, Hwang, ES, He, Y-W, Interleukin–10: an immune–activating cytokine in cancer immunotherapy. J CLin Oncol 34 (2016), 3576–3578.
-
(2016)
J CLin Oncol
, vol.34
, pp. 3576-3578
-
-
Zhang, H.1
Wang, Y.2
Hwang, E.S.3
He, Y.-W.4
-
100
-
-
84926609039
-
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
-
Platten, M, von Knebel Doeberitz, N, Oezen, I, Wick, W, Ochs, K, Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol, 5, 2015, 673.
-
(2015)
Front Immunol
, vol.5
, pp. 673
-
-
Platten, M.1
von Knebel Doeberitz, N.2
Oezen, I.3
Wick, W.4
Ochs, K.5
-
101
-
-
84994364943
-
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD–1 blockade
-
Pauken, KE, Sammons, MA, Odorizzi, PM, et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD–1 blockade. Science 354 (2016), 1160–1165.
-
(2016)
Science
, vol.354
, pp. 1160-1165
-
-
Pauken, K.E.1
Sammons, M.A.2
Odorizzi, P.M.3
-
102
-
-
84963614956
-
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
-
Tirosh, I, Izar, B, Prakadan, SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
-
(2016)
Science
, vol.352
, pp. 189-196
-
-
Tirosh, I.1
Izar, B.2
Prakadan, S.M.3
-
103
-
-
84929684999
-
Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets
-
Macosko, EZ, Basu, A, Satija, R, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 161 (2015), 1202–1214.
-
(2015)
Cell
, vol.161
, pp. 1202-1214
-
-
Macosko, E.Z.1
Basu, A.2
Satija, R.3
-
104
-
-
84996606989
-
Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip
-
Benam, KH, Novak, R, Nawroth, J, et al. Matched-comparative modeling of normal and diseased human airway responses using a microengineered breathing lung chip. Cell Systems 3 (2016), 456–466.
-
(2016)
Cell Systems
, vol.3
, pp. 456-466
-
-
Benam, K.H.1
Novak, R.2
Nawroth, J.3
-
105
-
-
84982175048
-
Genomic alteration-driven clinical trial designs in oncology
-
Simon, R, Genomic alteration-driven clinical trial designs in oncology. Ann Intern Med 165 (2016), 270–278.
-
(2016)
Ann Intern Med
, vol.165
, pp. 270-278
-
-
Simon, R.1
-
106
-
-
84947286516
-
Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility
-
Ignatiadis, M, Lee, M, Jeffrey, SS, Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility. Clin Cancer Res 21 (2015), 4786–4800.
-
(2015)
Clin Cancer Res
, vol.21
, pp. 4786-4800
-
-
Ignatiadis, M.1
Lee, M.2
Jeffrey, S.S.3
-
107
-
-
85016957443
-
From trial to target populations—calibrating real-world data
-
Najafzadeh, M, Schneeweiss, S, From trial to target populations—calibrating real-world data. N Engl J Med 376 (2017), 1203–1205.
-
(2017)
N Engl J Med
, vol.376
, pp. 1203-1205
-
-
Najafzadeh, M.1
Schneeweiss, S.2
-
108
-
-
85016289170
-
Advantages of a truly open-access data-sharing model
-
Bertagnolli, MM, Sartor, O, Chabner, BA, et al. Advantages of a truly open-access data-sharing model. N Engl J Med 376 (2017), 1178–1181.
-
(2017)
N Engl J Med
, vol.376
, pp. 1178-1181
-
-
Bertagnolli, M.M.1
Sartor, O.2
Chabner, B.A.3
-
109
-
-
85017428498
-
Drug development, trial design, and endpoints in oncology: adapting to rapidly changing science
-
Blumenthal, GM, Goldberg, KB, Pazdur, R, Drug development, trial design, and endpoints in oncology: adapting to rapidly changing science. Clin Pharmacol Ther 101 (2017), 572–574.
-
(2017)
Clin Pharmacol Ther
, vol.101
, pp. 572-574
-
-
Blumenthal, G.M.1
Goldberg, K.B.2
Pazdur, R.3
-
110
-
-
85018463691
-
Reevaluating eligibility criteria-balancing patient protection and participation in oncology trials
-
Beaver, JA, Ison, G, Pazdur, R, Reevaluating eligibility criteria-balancing patient protection and participation in oncology trials. N Engl J Med 376 (2017), 1504–1505.
-
(2017)
N Engl J Med
, vol.376
, pp. 1504-1505
-
-
Beaver, J.A.1
Ison, G.2
Pazdur, R.3
-
111
-
-
79952284127
-
Hallmarks of cancer: the next generation
-
Hanahan, D, Weinberg, RA, Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
112
-
-
79960915471
-
The third revolution: the convergence of the life sciences, physical sciences and engineerinG
-
(accessed Feb 17, 2017).
-
Sharp, PA, Cooney, CL, Kastern, MA, et al. The third revolution: the convergence of the life sciences, physical sciences and engineerinG. http://research.uc.edu/Libraries/Advanced_Seminar_Documents/MIT_White_Paper_on_Convergence_pd.sflb.ashx, 2011 (accessed Feb 17, 2017).
-
(2011)
-
-
Sharp, P.A.1
Cooney, C.L.2
Kastern, M.A.3
-
113
-
-
84987725265
-
A U.S. “Cancer Moonshot” to accelerate cancer research
-
Singer, DS, Jacks, T, Jaffee, E, A U.S. “Cancer Moonshot” to accelerate cancer research. Science 353 (2016), 1105–1106.
-
(2016)
Science
, vol.353
, pp. 1105-1106
-
-
Singer, D.S.1
Jacks, T.2
Jaffee, E.3
-
114
-
-
84897143486
-
The $1,000 genome
-
Hayden, EC, The $1,000 genome. Nature, 507, 2014, 295.
-
(2014)
Nature
, vol.507
, pp. 295
-
-
Hayden, E.C.1
-
115
-
-
85010936415
-
DNA sequencing technologies: 2006–2016
-
Mardis, ER, DNA sequencing technologies: 2006–2016. Nat Protoc 12 (2017), 213–218.
-
(2017)
Nat Protoc
, vol.12
, pp. 213-218
-
-
Mardis, E.R.1
-
117
-
-
84923106217
-
Therapeutic genome editing: prospects and challenges
-
Cox, DBT, Platt, RJ, Zhang, F, Therapeutic genome editing: prospects and challenges. Nat Med 21 (2015), 121–131.
-
(2015)
Nat Med
, vol.21
, pp. 121-131
-
-
Cox, D.B.T.1
Platt, R.J.2
Zhang, F.3
-
118
-
-
84959852078
-
Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering
-
Kelley, SO, Mirkin, CA, Walt, DR, Ismagilov, RF, Toner, M, Sargent, EH, Advancing the speed, sensitivity and accuracy of biomolecular detection using multi-length-scale engineering. Nat Nanotechnol 9 (2014), 969–980.
-
(2014)
Nat Nanotechnol
, vol.9
, pp. 969-980
-
-
Kelley, S.O.1
Mirkin, C.A.2
Walt, D.R.3
Ismagilov, R.F.4
Toner, M.5
Sargent, E.H.6
-
119
-
-
85029919483
-
Ultrasensitive tumour-penetrating nanosensors of protease activity
-
published online April 10.
-
Kwon, EJ, Dudani, JS, Bhatia, SN, Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat Biomed Eng, 2017 published online April 10. DOI:10.1038/s41551-017-0054.
-
(2017)
Nat Biomed Eng
-
-
Kwon, E.J.1
Dudani, J.S.2
Bhatia, S.N.3
-
120
-
-
84872176550
-
Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease
-
Kwong, GA, von Maltzahn, G, Murugappan, G, et al. Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. Nat Biotechnol 31 (2013), 63–70.
-
(2013)
Nat Biotechnol
, vol.31
, pp. 63-70
-
-
Kwong, G.A.1
von Maltzahn, G.2
Murugappan, G.3
-
121
-
-
84928677711
-
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
-
Jonas, O, Landry, HM, Fuller, JE, et al. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci Transl Med, 7, 2015, 284ra57.
-
(2015)
Sci Transl Med
, vol.7
, pp. 284ra57
-
-
Jonas, O.1
Landry, H.M.2
Fuller, J.E.3
-
122
-
-
84946215806
-
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids
-
Huang, L, Holtzinger, A, Jagan, I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med 21 (2015), 1364–1371.
-
(2015)
Nat Med
, vol.21
, pp. 1364-1371
-
-
Huang, L.1
Holtzinger, A.2
Jagan, I.3
-
123
-
-
84908576857
-
Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe
-
Phillips, E, Penate-Medina, O, Zanzonico, PB, et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med, 6, 2014, 260ra149.
-
(2014)
Sci Transl Med
, vol.6
, pp. 260ra149
-
-
Phillips, E.1
Penate-Medina, O.2
Zanzonico, P.B.3
-
124
-
-
85042185090
-
Merck and Moderna announce strategic collaboration to advance novel mRNA-based personalized cancer vaccines with KEYTRUDA (pembrolizumab) for the treatment of multiple types of cancer
-
(accessed May 8, 2017).
-
Moderna Therapeutics. Merck and Moderna announce strategic collaboration to advance novel mRNA-based personalized cancer vaccines with KEYTRUDA (pembrolizumab) for the treatment of multiple types of cancer. https://www.modernatx.com/newsroom/press-releases/merck-and-moderna-announce-strategic-collaboration-advance-novel-mrna-based, June 29, 2016 (accessed May 8, 2017).
-
(2016)
-
-
-
125
-
-
84877120847
-
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement
-
Tabernero, J, Shapiro, GI, LoRusso, PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3 (2013), 406–417.
-
(2013)
Cancer Discov
, vol.3
, pp. 406-417
-
-
Tabernero, J.1
Shapiro, G.I.2
LoRusso, P.M.3
-
126
-
-
78650624101
-
RNA interference in the clinic: challenges and future directions
-
Pecot, CV, Calin, GA, Coleman, RL, Lopez-Berestein, G, Sood, AK, RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11 (2010), 59–67.
-
(2010)
Nat Rev Cancer
, vol.11
, pp. 59-67
-
-
Pecot, C.V.1
Calin, G.A.2
Coleman, R.L.3
Lopez-Berestein, G.4
Sood, A.K.5
-
127
-
-
84900563057
-
A Nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways
-
Morton, SW, Lee, MJ, Deng, ZJ, et al. A Nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal, 7, 2014, ra44.
-
(2014)
Sci Signal
, vol.7
, pp. ra44
-
-
Morton, S.W.1
Lee, M.J.2
Deng, Z.J.3
-
128
-
-
84990855364
-
Engineering T cells with customized therapeutic response programs using synthetic notch receptors
-
Roybal, KT, Williams, JZ, Morsut, L, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167 (2016), 419–432.
-
(2016)
Cell
, vol.167
, pp. 419-432
-
-
Roybal, K.T.1
Williams, J.Z.2
Morsut, L.3
-
129
-
-
85017503720
-
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
-
Smith, TT, Stephan, SB, Moffett, HF, et al. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. Nat Nanotechnol 12 (2017), 813–820.
-
(2017)
Nat Nanotechnol
, vol.12
, pp. 813-820
-
-
Smith, T.T.1
Stephan, S.B.2
Moffett, H.F.3
-
130
-
-
84927130807
-
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
-
Sharma, P, Allison, JP, Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
-
(2015)
Cell
, vol.161
, pp. 205-214
-
-
Sharma, P.1
Allison, J.P.2
-
131
-
-
84938350452
-
Combination cancer immunotherapy and new immunomodulatory targets
-
Mahoney, KM, Rennert, PD, Freeman, GJ, Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 14 (2015), 561–584.
-
(2015)
Nat Rev Drug Discov
, vol.14
, pp. 561-584
-
-
Mahoney, K.M.1
Rennert, P.D.2
Freeman, G.J.3
-
132
-
-
85006459521
-
Combination Approaches with Immune–Checkpoint Blockade in Cancer Therapy
-
Swart, M, Verbrugge, I, Beltman, JB, Combination Approaches with Immune–Checkpoint Blockade in Cancer Therapy. Front Oncol, 6, 2016, 233.
-
(2016)
Front Oncol
, vol.6
, pp. 233
-
-
Swart, M.1
Verbrugge, I.2
Beltman, J.B.3
-
133
-
-
84928761118
-
Mutational landscape determines sensitivity to PD–1 blockade in non–small cell lung cancer
-
Rizvi, NA, Hellmann, MD, Snyder, A, et al. Mutational landscape determines sensitivity to PD–1 blockade in non–small cell lung cancer. Science 348 (2015), 124–128.
-
(2015)
Science
, vol.348
, pp. 124-128
-
-
Rizvi, N.A.1
Hellmann, M.D.2
Snyder, A.3
-
134
-
-
85002396993
-
T-cell transfer therapy targeting mutant KRAS in cancer
-
Tran, E, Robbins, PF, Lu, Y-C, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 375 (2016), 2255–2262.
-
(2016)
N Engl J Med
, vol.375
, pp. 2255-2262
-
-
Tran, E.1
Robbins, P.F.2
Lu, Y.-C.3
-
135
-
-
85042194378
-
Gut bacteria associated with cancer immunotherapy response in melanoma
-
University of Texas M D Anderson Cancer Center. Gut bacteria associated with cancer immunotherapy response in melanoma. ScienceDaily, Feb 21, 2017.
-
(2017)
ScienceDaily
-
-
-
136
-
-
85007427057
-
Driving gene-engineered T cell immunotherapy of cancer
-
Johnson, LA, June, CH, Driving gene-engineered T cell immunotherapy of cancer. Cell Res 27 (2017), 38–58.
-
(2017)
Cell Res
, vol.27
, pp. 38-58
-
-
Johnson, L.A.1
June, C.H.2
-
137
-
-
85007529846
-
A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
-
Zhang, E, Xu, H, A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J Hematol Oncol, 10, 2017, 1.
-
(2017)
J Hematol Oncol
, vol.10
, pp. 1
-
-
Zhang, E.1
Xu, H.2
-
138
-
-
85018387101
-
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
-
Ren, J, Liu, X, Fang, C, Jiang, S, June, CH, Zhao, Y, Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 23 (2016), 2255–2266.
-
(2016)
Clin Cancer Res
, vol.23
, pp. 2255-2266
-
-
Ren, J.1
Liu, X.2
Fang, C.3
Jiang, S.4
June, C.H.5
Zhao, Y.6
-
139
-
-
79958043675
-
-
National Cancer Institute Bethesda, MD
-
Howlader, N, Noone, AM, Krapcho, M, et al. SEER cancer statistics review, 1975–2013, 2016, National Cancer Institute, Bethesda, MD.
-
(2016)
SEER cancer statistics review, 1975–2013
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
-
140
-
-
84891018674
-
Survivors of childhood and adolescent cancer: life-long risks and responsibilities
-
Robison, LL, Hudson, MM, Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer 14 (2014), 61–70.
-
(2014)
Nat Rev Cancer
, vol.14
, pp. 61-70
-
-
Robison, L.L.1
Hudson, M.M.2
-
141
-
-
84878854824
-
Clinical ascertainment of health outcomes among adults treated for childhood cancer
-
Hudson, MM, Ness, KK, Gurney, JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 12 (2013), 2371–2381.
-
(2013)
JAMA
, vol.12
, pp. 2371-2381
-
-
Hudson, M.M.1
Ness, K.K.2
Gurney, J.G.3
-
142
-
-
84994517579
-
Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study
-
Bhakta, N, Liu, N, Yeo, F, et al. Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study. Lancet Oncol 17 (2016), 1325–1334.
-
(2016)
Lancet Oncol
, vol.17
, pp. 1325-1334
-
-
Bhakta, N.1
Liu, N.2
Yeo, F.3
-
143
-
-
65549140230
-
Social outcomes in the Childhood Cancer Survivor Study Cohort
-
Gurney, JG, Krull, KR, Kadan-Lottick, NS, et al. Social outcomes in the Childhood Cancer Survivor Study Cohort. J Clin Oncol 27 (2009), 2390–2395.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2390-2395
-
-
Gurney, J.G.1
Krull, K.R.2
Kadan-Lottick, N.S.3
-
144
-
-
77449117312
-
Suicidal ideation in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
-
Recklitis, CJ, Diller, LR, Li, X, Najita, J, Robison, LL, Zeltzer, LK, Suicidal ideation in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J Clin Oncol 28 (2010), 655–661.
-
(2010)
J Clin Oncol
, vol.28
, pp. 655-661
-
-
Recklitis, C.J.1
Diller, L.R.2
Li, X.3
Najita, J.4
Robison, L.L.5
Zeltzer, L.K.6
-
145
-
-
77951242627
-
A model-based estimate of cumulative excess mortality in survivors of childhood cancer
-
Yeh, JM, Nekhlyudov, L, Goldie, SJ, Mertens, AC, Diller, LR, A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med 152 (2010), 409–417.
-
(2010)
Ann Intern Med
, vol.152
, pp. 409-417
-
-
Yeh, J.M.1
Nekhlyudov, L.2
Goldie, S.J.3
Mertens, A.C.4
Diller, L.R.5
-
146
-
-
84872773655
-
21st-century hazards of smoking and benefits of cessation in the United States
-
Jha, P, Ramasundarahettige, C, Landsman, V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 368 (2013), 341–350.
-
(2013)
N Engl J Med
, vol.368
, pp. 341-350
-
-
Jha, P.1
Ramasundarahettige, C.2
Landsman, V.3
-
147
-
-
84959377864
-
Impact of socioeconomic status on timing of relapse and overall survival for children treated on Dana-Farber Cancer Institute ALL Consortium protocols (2000–2010)
-
Bona, K, Blonquist, TM, Neuberg, DS, Silverman, LB, Wolfe, J, Impact of socioeconomic status on timing of relapse and overall survival for children treated on Dana-Farber Cancer Institute ALL Consortium protocols (2000–2010). Pediatr Blood Cancer 63 (2016), 1012–1018.
-
(2016)
Pediatr Blood Cancer
, vol.63
, pp. 1012-1018
-
-
Bona, K.1
Blonquist, T.M.2
Neuberg, D.S.3
Silverman, L.B.4
Wolfe, J.5
-
148
-
-
84937725648
-
Adolescent and young adult cancer survival
-
Lewis, DR, Seibel, NL, Smith, AW, Stedman, MR, Adolescent and young adult cancer survival. J Natl Cancer Inst Monogr 49 (2014), 228–235.
-
(2014)
J Natl Cancer Inst Monogr
, vol.49
, pp. 228-235
-
-
Lewis, D.R.1
Seibel, N.L.2
Smith, A.W.3
Stedman, M.R.4
-
149
-
-
84960422100
-
Guideline for the treatment of breakthrough and the prevention of chemotherapy-induced nausea and vomiting in children with cancer
-
Flank, J, Robinson, PD, Holdsworth, M, et al. Guideline for the treatment of breakthrough and the prevention of chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer 63 (2016), 1144–1151.
-
(2016)
Pediatr Blood Cancer
, vol.63
, pp. 1144-1151
-
-
Flank, J.1
Robinson, P.D.2
Holdsworth, M.3
-
150
-
-
84896987650
-
Prevention and treatment of oral mucositis in children with cancer
-
Miller, MM, Donald, DV, Hagemann, TM, Prevention and treatment of oral mucositis in children with cancer. J Pediatr Pharmacol Ther 17 (2012), 340–350.
-
(2012)
J Pediatr Pharmacol Ther
, vol.17
, pp. 340-350
-
-
Miller, M.M.1
Donald, D.V.2
Hagemann, T.M.3
-
151
-
-
84994545580
-
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li–Fraumeni syndrome: 11 year follow–up of a prospective observational study
-
Villani, A, Shore, A, Wasserman, JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li–Fraumeni syndrome: 11 year follow–up of a prospective observational study. Lancet Oncol 17 (2016), 1295–1305.
-
(2016)
Lancet Oncol
, vol.17
, pp. 1295-1305
-
-
Villani, A.1
Shore, A.2
Wasserman, J.D.3
-
152
-
-
84949449519
-
Germline mutations in predisposition genes in pediatric cancer
-
Zhang, J, Walsh, MF, Wu, G, et al. Germline mutations in predisposition genes in pediatric cancer. New Engl J Med 373 (2015), 2336–2346.
-
(2015)
New Engl J Med
, vol.373
, pp. 2336-2346
-
-
Zhang, J.1
Walsh, M.F.2
Wu, G.3
-
153
-
-
65549169968
-
The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research
-
Robison, LL, Armstrong, GT, Boice, JD, et al. The Childhood Cancer Survivor Study: A National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 27 (2009), 2308–2318.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2308-2318
-
-
Robison, L.L.1
Armstrong, G.T.2
Boice, J.D.3
-
154
-
-
85019243142
-
Approach for classification and severity–grading of long–term health events among childhood cancer survivors in the St. Jude Lifetime Cohort
-
Hudson, MM, Ehrhardt, MJ, Bhakta, N, et al. Approach for classification and severity–grading of long–term health events among childhood cancer survivors in the St. Jude Lifetime Cohort. Cancer Epidemiol Biomarkers Prev 26 (2016), 666–674.
-
(2016)
Cancer Epidemiol Biomarkers Prev
, vol.26
, pp. 666-674
-
-
Hudson, M.M.1
Ehrhardt, M.J.2
Bhakta, N.3
-
155
-
-
34250839958
-
Health-status of adult survivors of childhood cancer: A large-scale population-based study from the British childhood cancer survivor study
-
Reulen, RC, Winter, DL, Lancashire, ER, et al. Health-status of adult survivors of childhood cancer: A large-scale population-based study from the British childhood cancer survivor study. Int J Cancer 121 (2007), 633–640.
-
(2007)
Int J Cancer
, vol.121
, pp. 633-640
-
-
Reulen, R.C.1
Winter, D.L.2
Lancashire, E.R.3
-
156
-
-
84903604562
-
Aging and risk of severe, disabling, life–threatening, and fatal events in the Childhood Cancer Survivor Study
-
Armstrong, GT, Kawashima, T, Leisenring, W, et al. Aging and risk of severe, disabling, life–threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol 32 (2014), 1218–1227.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1218-1227
-
-
Armstrong, G.T.1
Kawashima, T.2
Leisenring, W.3
-
157
-
-
84959532264
-
Reduction in late mortality among 5-year survivors of childhood cancer
-
Armstrong, GT, Chen, Y, Yasui, Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med 374 (2016), 833–842.
-
(2016)
N Engl J Med
, vol.374
, pp. 833-842
-
-
Armstrong, G.T.1
Chen, Y.2
Yasui, Y.3
-
158
-
-
70649113052
-
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
-
Ross, CJ, Katzov-Eckert, H, Dubé MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41 (2009), 1345–1349.
-
(2009)
Nat Genet
, vol.41
, pp. 1345-1349
-
-
Ross, C.J.1
Katzov-Eckert, H.2
Dubé, M.P.3
-
159
-
-
84863001655
-
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children
-
Visscher, H, Ross, CJ, Rassekh, SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 30 (2012), 1422–1428.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1422-1428
-
-
Visscher, H.1
Ross, C.J.2
Rassekh, S.R.3
-
160
-
-
31144442120
-
The ‘Lost Tribe’ and the need for a promised land: the challenge of cancer in teenagers and young adults
-
Stevens, MC, The ‘Lost Tribe’ and the need for a promised land: the challenge of cancer in teenagers and young adults. Eur J Cancer 42 (2006), 280–281.
-
(2006)
Eur J Cancer
, vol.42
, pp. 280-281
-
-
Stevens, M.C.1
-
161
-
-
65549147127
-
Cancer in young adults: 20 to 39 years of age: overview
-
Bleyer, A, Barr, R, Cancer in young adults: 20 to 39 years of age: overview. Semin Oncol 36 (2009), 194–206.
-
(2009)
Semin Oncol
, vol.36
, pp. 194-206
-
-
Bleyer, A.1
Barr, R.2
-
162
-
-
35648939837
-
Site of oncologic speciatly care for older adolscents in Utah
-
Albritton, KH, Wiggins, CH, Nelson, HE, Weeks, JC, Site of oncologic speciatly care for older adolscents in Utah. J Clin Oncol 25 (2007), 4616–4621.
-
(2007)
J Clin Oncol
, vol.25
, pp. 4616-4621
-
-
Albritton, K.H.1
Wiggins, C.H.2
Nelson, H.E.3
Weeks, J.C.4
-
163
-
-
84994037386
-
Adoption of pediatric-inspired acute lymphoblastic-leukemia regimens by adult oncologists treating adolescents and young adults: a population-based study
-
Muffly, L, Kichtensztajn, D, Shiraz, P, et al. Adoption of pediatric-inspired acute lymphoblastic-leukemia regimens by adult oncologists treating adolescents and young adults: a population-based study. Cancer 123 (2017), 122–130.
-
(2017)
Cancer
, vol.123
, pp. 122-130
-
-
Muffly, L.1
Kichtensztajn, D.2
Shiraz, P.3
-
164
-
-
84963829157
-
Accrual of adolescents and young adults with cancer to clinical trials
-
Hay, AE, Rae, C, Fraser, GAM, et al. Accrual of adolescents and young adults with cancer to clinical trials. Curr Oncol 23 (2016), e81–e85.
-
(2016)
Curr Oncol
, vol.23
, pp. e81-e85
-
-
Hay, A.E.1
Rae, C.2
Fraser, G.A.M.3
-
165
-
-
84856223787
-
Rhabdomyosarcoma in adolescents: a report from teh AIEOP Soft Tissue Sarcoma Committee
-
Bisogno, G, Compostella, A, Ferrari, A, et al. Rhabdomyosarcoma in adolescents: a report from teh AIEOP Soft Tissue Sarcoma Committee. Cancer 118 (2012), 821–827.
-
(2012)
Cancer
, vol.118
, pp. 821-827
-
-
Bisogno, G.1
Compostella, A.2
Ferrari, A.3
-
166
-
-
84863923825
-
Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non–Hispanic white children with acute lymphoblastic leukemia: a report from the Children's Oncology Group
-
Bhatia, S, Landier, W, Shangguan, M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non–Hispanic white children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 30 (2012), 2094–2101.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2094-2101
-
-
Bhatia, S.1
Landier, W.2
Shangguan, M.3
-
167
-
-
84866884531
-
Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert testimony in lawsuits
-
Brasme, JF, Morfouace, M, Grill, J, et al. Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert testimony in lawsuits. Lancet Oncol 13 (2012), e445–e459.
-
(2012)
Lancet Oncol
, vol.13
, pp. e445-e459
-
-
Brasme, J.F.1
Morfouace, M.2
Grill, J.3
-
168
-
-
84888015278
-
Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescents/young adult and younger patients
-
Canner, J, Alonzo, TA, Franklin, J, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescents/young adult and younger patients. Cancer 119 (2013), 4162–4169.
-
(2013)
Cancer
, vol.119
, pp. 4162-4169
-
-
Canner, J.1
Alonzo, T.A.2
Franklin, J.3
-
169
-
-
84924412997
-
Long-term outcome of a pediatric inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia
-
DeAngelo, DJ, Stevenson, KE, Dalhberg, SE, et al. Long-term outcome of a pediatric inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29 (2015), 526–534.
-
(2015)
Leukemia
, vol.29
, pp. 526-534
-
-
DeAngelo, D.J.1
Stevenson, K.E.2
Dalhberg, S.E.3
-
170
-
-
84927776117
-
Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US Intergroup Trial C10403
-
Stock, W, Luger, SM, Advani, AS, et al. Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US Intergroup Trial C10403. Blood, 124, 2014, 796.
-
(2014)
Blood
, vol.124
, pp. 796
-
-
Stock, W.1
Luger, S.M.2
Advani, A.S.3
-
171
-
-
84986625687
-
Use of appropriate initial treatment among adolescents and young adults with cancer
-
Potosky, AL, Harlan, LC, Albritton, K, et al. Use of appropriate initial treatment among adolescents and young adults with cancer. J Natl Cancer Inst, 106, 2014, dju300.
-
(2014)
J Natl Cancer Inst
, vol.106
, pp. dju300
-
-
Potosky, A.L.1
Harlan, L.C.2
Albritton, K.3
-
172
-
-
84884517643
-
Young adult cancer services in the UK: the journey to a national network
-
Carr, R, Whiteson, M, Edwards, M, Morgan, S, Young adult cancer services in the UK: the journey to a national network. Clin Med 13 (2013), 258–262.
-
(2013)
Clin Med
, vol.13
, pp. 258-262
-
-
Carr, R.1
Whiteson, M.2
Edwards, M.3
Morgan, S.4
-
173
-
-
84896308804
-
Low socioeconomic status is associated with worse survival in children with cancer: a systematic review
-
Gupta, S, Wilejto, M, Pole, JD, Guttmann, A, Sung, L, Low socioeconomic status is associated with worse survival in children with cancer: a systematic review. PLoS One, 9, 2014, e89482.
-
(2014)
PLoS One
, vol.9
, pp. e89482
-
-
Gupta, S.1
Wilejto, M.2
Pole, J.D.3
Guttmann, A.4
Sung, L.5
-
174
-
-
84903278539
-
Pediatric oncology as the next global child health priority: the need for national childhood cancer strategies in low- and middle-income countries
-
Gupta, S, Rivera-Luna, R, Ribeiro, R, Howard, SC, Pediatric oncology as the next global child health priority: the need for national childhood cancer strategies in low- and middle-income countries. PLoS Med, 11, 2014, e1001656.
-
(2014)
PLoS Med
, vol.11
, pp. e1001656
-
-
Gupta, S.1
Rivera-Luna, R.2
Ribeiro, R.3
Howard, S.C.4
-
175
-
-
84958093148
-
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
-
Moriyami, T, Nishii, R, Perez-Andreu, V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet 48 (2016), 367–373.
-
(2016)
Nat Genet
, vol.48
, pp. 367-373
-
-
Moriyami, T.1
Nishii, R.2
Perez-Andreu, V.3
-
176
-
-
75249092032
-
Teleoncology: current and future applications for improving cancer care globally
-
Hazin, R, Qaddoumi, I, Teleoncology: current and future applications for improving cancer care globally. Lancet Oncol 11 (2010), 204–210.
-
(2010)
Lancet Oncol
, vol.11
, pp. 204-210
-
-
Hazin, R.1
Qaddoumi, I.2
-
177
-
-
84862249169
-
Improving the histopathologic diagnosis of pediatric malignancies in a low-resource setting by combining focused training and telepathology strategies
-
Santiago, TC, Jenkins, JJ, Pedrosa, F, et al. Improving the histopathologic diagnosis of pediatric malignancies in a low-resource setting by combining focused training and telepathology strategies. Pediatr Blood Cancer 59 (2012), 221–225.
-
(2012)
Pediatr Blood Cancer
, vol.59
, pp. 221-225
-
-
Santiago, T.C.1
Jenkins, J.J.2
Pedrosa, F.3
-
178
-
-
84888802466
-
Statistics
-
(accessed Sept 21, 2017).
-
Office of Cancer Survivorship Division of Cancer Control & Population Sciences, National Cancer Institute. Statistics. https://cancercontrol.cancer.gov/ocs/statistics/statistics.html (accessed Sept 21, 2017).
-
-
-
-
180
-
-
79960112592
-
Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina
-
Mayer, DK, Travers, D, Wyss, A, Leak, A, Waller, A, Why do patients with cancer visit emergency departments? Results of a 2008 population study in North Carolina. J Clin Oncol 29 (2011), 2683–2688.
-
(2011)
J Clin Oncol
, vol.29
, pp. 2683-2688
-
-
Mayer, D.K.1
Travers, D.2
Wyss, A.3
Leak, A.4
Waller, A.5
-
181
-
-
82955195816
-
Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer
-
Nekhlyudov, L, Li, L, Ross-Degnan, D, Wagner, AK, Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 130 (2011), 681–689.
-
(2011)
Breast Cancer Res Treat
, vol.130
, pp. 681-689
-
-
Nekhlyudov, L.1
Li, L.2
Ross-Degnan, D.3
Wagner, A.K.4
-
182
-
-
84874667686
-
A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians
-
Huiart, L, Ferdynus, C, Giorgi, R, A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. Breast Cancer Res Treat 138 (2013), 325–328.
-
(2013)
Breast Cancer Res Treat
, vol.138
, pp. 325-328
-
-
Huiart, L.1
Ferdynus, C.2
Giorgi, R.3
-
183
-
-
84929467361
-
Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial
-
Bakitas, MA, Tosteson, TD, Li, Z, et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol 33 (2015), 1438–1445.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1438-1445
-
-
Bakitas, M.A.1
Tosteson, T.D.2
Li, Z.3
-
184
-
-
79960577663
-
A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer
-
Gilbertson-White, S, Aouizerat, BE, Jahan, T, Miaskowski, C, A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer. Palliat Support Care 9 (2011), 81–102.
-
(2011)
Palliat Support Care
, vol.9
, pp. 81-102
-
-
Gilbertson-White, S.1
Aouizerat, B.E.2
Jahan, T.3
Miaskowski, C.4
-
185
-
-
77955877759
-
Early palliative care for patients with metastatic non–small–cell lung cancer
-
Temel, JS, Greer, JA, Muzikansky, A, et al. Early palliative care for patients with metastatic non–small–cell lung cancer. N Engl J Med 363 (2010), 733–742.
-
(2010)
N Engl J Med
, vol.363
, pp. 733-742
-
-
Temel, J.S.1
Greer, J.A.2
Muzikansky, A.3
-
186
-
-
68949090752
-
Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial
-
Bakitas, M, Lyons, KD, Hegel, MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 302 (2009), 741–749.
-
(2009)
JAMA
, vol.302
, pp. 741-749
-
-
Bakitas, M.1
Lyons, K.D.2
Hegel, M.T.3
-
187
-
-
85009923590
-
Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update
-
Ferrell, BR, Temel, JS, Temin, S, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35 (2017), 96–112.
-
(2017)
J Clin Oncol
, vol.35
, pp. 96-112
-
-
Ferrell, B.R.1
Temel, J.S.2
Temin, S.3
-
188
-
-
85020425017
-
Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment
-
Basch, E, Deal, AM, Dueck, AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318 (2017), 197–198.
-
(2017)
JAMA
, vol.318
, pp. 197-198
-
-
Basch, E.1
Deal, A.M.2
Dueck, A.C.3
-
189
-
-
78149250018
-
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
-
Ingle, JN, Schaid, DJ, Goss, PE, et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28 (2010), 4674–4682.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4674-4682
-
-
Ingle, J.N.1
Schaid, D.J.2
Goss, P.E.3
-
190
-
-
84934324585
-
Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance)
-
Boora, GK, Kulkarni, AA, Kanwar, R, et al. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci 357 (2015), 35–40.
-
(2015)
J Neurol Sci
, vol.357
, pp. 35-40
-
-
Boora, G.K.1
Kulkarni, A.A.2
Kanwar, R.3
-
191
-
-
84981765193
-
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)
-
Boora, GK, Kanwar, R, Kulkarni, AA, et al. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Cancer Med 5 (2016), 631–639.
-
(2016)
Cancer Med
, vol.5
, pp. 631-639
-
-
Boora, G.K.1
Kanwar, R.2
Kulkarni, A.A.3
-
192
-
-
84962167822
-
Scrambler Therapy for the management of chronic pain
-
Majithia, N, Smith, TJ, Coyne, PJ, et al. Scrambler Therapy for the management of chronic pain. Support Care Cancer 24 (2016), 2807–2814.
-
(2016)
Support Care Cancer
, vol.24
, pp. 2807-2814
-
-
Majithia, N.1
Smith, T.J.2
Coyne, P.J.3
-
193
-
-
85009286571
-
Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence
-
Astrup, GL, Hofsø K, Bjordal, K, et al. Patient factors and quality of life outcomes differ among four subgroups of oncology patients based on symptom occurrence. Acta Oncol 56 (2017), 462–470.
-
(2017)
Acta Oncol
, vol.56
, pp. 462-470
-
-
Astrup, G.L.1
Hofsø, K.2
Bjordal, K.3
-
194
-
-
34249089533
-
Symptom control trials: a 20–year experience
-
Loprinzi, CL, Barton, DL, Jatoi, A, et al. Symptom control trials: a 20–year experience. J Support Oncol 5 (2007), 119–128.
-
(2007)
J Support Oncol
, vol.5
, pp. 119-128
-
-
Loprinzi, C.L.1
Barton, D.L.2
Jatoi, A.3
-
195
-
-
0025302267
-
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia
-
Loprinzi, CL, Ellison, NM, Schaid, DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82 (1990), 1127–1132.
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 1127-1132
-
-
Loprinzi, C.L.1
Ellison, N.M.2
Schaid, D.J.3
-
196
-
-
0033521964
-
Lack of effect of coumarin in women with lymphedema after treatment for breast cancer
-
Loprinzi, CL, Kugler, JW, Sloan, JA, et al. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med 340 (1999), 346–350.
-
(1999)
N Engl J Med
, vol.340
, pp. 346-350
-
-
Loprinzi, C.L.1
Kugler, J.W.2
Sloan, J.A.3
-
197
-
-
0028085970
-
Megestrol acetate for the prevention of hot flashes
-
Loprinzi, CL, Michalak, JC, Quella, SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 331 (1994), 347–352.
-
(1994)
N Engl J Med
, vol.331
, pp. 347-352
-
-
Loprinzi, C.L.1
Michalak, J.C.2
Quella, S.K.3
-
198
-
-
34249713221
-
Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3
-
Barton, DL, Wender, DB, Sloan, JA, et al. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3. J Natl Cancer Inst 99 (2007), 672–679.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 672-679
-
-
Barton, D.L.1
Wender, D.B.2
Sloan, J.A.3
-
199
-
-
0036299151
-
Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy
-
Hammack, JE, Michalak, JC, Loprinzi, CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98 (2002), 195–203.
-
(2002)
Pain
, vol.98
, pp. 195-203
-
-
Hammack, J.E.1
Michalak, J.C.2
Loprinzi, C.L.3
-
200
-
-
85014016250
-
Perceived cognitive function for breast cancer survivors: association of genetic and behaviourally related variables for inflammation
-
Myers, JS, Koleck, TA, Sereika, SM, Conley, YP, Bender, CM, Perceived cognitive function for breast cancer survivors: association of genetic and behaviourally related variables for inflammation. Support Care Cancer 25 (2017), 2475–2484.
-
(2017)
Support Care Cancer
, vol.25
, pp. 2475-2484
-
-
Myers, J.S.1
Koleck, T.A.2
Sereika, S.M.3
Conley, Y.P.4
Bender, C.M.5
-
201
-
-
84937520484
-
Patterns of change in cognitive function with anastrozole therapy
-
Bender, CM, Merriman, JD, Gentry, AL, et al. Patterns of change in cognitive function with anastrozole therapy. Cancer 121 (2015), 2627–2636.
-
(2015)
Cancer
, vol.121
, pp. 2627-2636
-
-
Bender, C.M.1
Merriman, J.D.2
Gentry, A.L.3
-
202
-
-
84953634860
-
Cancer-related fatigue and associated disability in post-treatment cancer survivors
-
Jones, JM, Olson, K, Catton, P, et al. Cancer-related fatigue and associated disability in post-treatment cancer survivors. J Cancer Surviv 10 (2016), 51–61.
-
(2016)
J Cancer Surviv
, vol.10
, pp. 51-61
-
-
Jones, J.M.1
Olson, K.2
Catton, P.3
-
203
-
-
84981238908
-
Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk
-
Bao, T, Basal, C, Seluzicki, C, Li, SQ, Seidman, AD, Mao, JJ, Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159 (2016), 327–333.
-
(2016)
Breast Cancer Res Treat
, vol.159
, pp. 327-333
-
-
Bao, T.1
Basal, C.2
Seluzicki, C.3
Li, S.Q.4
Seidman, A.D.5
Mao, J.J.6
-
204
-
-
84978062965
-
The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling
-
Kolb, NA, Smith, AG, Singleton, JR, et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 73 (2016), 860–866.
-
(2016)
JAMA Neurol
, vol.73
, pp. 860-866
-
-
Kolb, N.A.1
Smith, A.G.2
Singleton, J.R.3
-
205
-
-
84957921922
-
Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial
-
Tashakori Beheshti, A, Mostafavi Toroghi, H, Hosseini, G, Zarifian, A, Homaei Shandiz, F, Fazlinezhad, A, Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology 134 (2016), 47–53.
-
(2016)
Cardiology
, vol.134
, pp. 47-53
-
-
Tashakori Beheshti, A.1
Mostafavi Toroghi, H.2
Hosseini, G.3
Zarifian, A.4
Homaei Shandiz, F.5
Fazlinezhad, A.6
-
206
-
-
84973281958
-
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol
-
Gulati, G, Heck, SL, Ree, AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37 (2016), 1671–1680.
-
(2016)
Eur Heart J
, vol.37
, pp. 1671-1680
-
-
Gulati, G.1
Heck, S.L.2
Ree, A.H.3
-
207
-
-
84923269274
-
Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia
-
Diouf, B, Crews, KR, Lew, G, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313 (2015), 815–823.
-
(2015)
JAMA
, vol.313
, pp. 815-823
-
-
Diouf, B.1
Crews, K.R.2
Lew, G.3
-
208
-
-
84883172515
-
Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy
-
Leandro-Garcia, LJ, Inglada-Perez, L, Pita, G, et al. Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet 50 (2013), 599–605.
-
(2013)
J Med Genet
, vol.50
, pp. 599-605
-
-
Leandro-Garcia, L.J.1
Inglada-Perez, L.2
Pita, G.3
-
209
-
-
85008643932
-
Emotional distress impacts quality of life evaluation: a report from the Childhood Cancer Survivor Study
-
Huang, IC, Brinkman, TM, Armstrong, GT, Leisenring, W, Robison, LL, Krull, KR, Emotional distress impacts quality of life evaluation: a report from the Childhood Cancer Survivor Study. J Cancer Surviv 11 (2017), 309–319.
-
(2017)
J Cancer Surviv
, vol.11
, pp. 309-319
-
-
Huang, I.C.1
Brinkman, T.M.2
Armstrong, G.T.3
Leisenring, W.4
Robison, L.L.5
Krull, K.R.6
-
210
-
-
84874109218
-
Does fear of cancer recurrence predict cancer survivors' health care use?
-
Lebel, S, Tomei, C, Feldstain, A, Beattie, S, McCallum, M, Does fear of cancer recurrence predict cancer survivors' health care use?. Support Care Cancer 21 (2013), 901–906.
-
(2013)
Support Care Cancer
, vol.21
, pp. 901-906
-
-
Lebel, S.1
Tomei, C.2
Feldstain, A.3
Beattie, S.4
McCallum, M.5
-
211
-
-
84952907904
-
The growth of palliative care in U.S. hospitals: a status report
-
Dumanovsky, T, Augustin, R, Rogers, M, Lettang, K, Meier, DE, Morrison, RS, The growth of palliative care in U.S. hospitals: a status report. J Palliat Med 19 (2016), 8–15.
-
(2016)
J Palliat Med
, vol.19
, pp. 8-15
-
-
Dumanovsky, T.1
Augustin, R.2
Rogers, M.3
Lettang, K.4
Meier, D.E.5
Morrison, R.S.6
-
212
-
-
78649933024
-
Estimate of current hospice and palliative medicine physician workforce shortage
-
Lupu, D, American Academy of Hospice and Palliative Medicine Workforce Task Force. Estimate of current hospice and palliative medicine physician workforce shortage. J Pain Symptom Manage 40 (2010), 899–911.
-
(2010)
J Pain Symptom Manage
, vol.40
, pp. 899-911
-
-
Lupu, D.1
-
214
-
-
84859350578
-
Developing the science of end-of-life and palliative care research: National Institute of Nursing Research summit
-
Csikai, EL, Developing the science of end-of-life and palliative care research: National Institute of Nursing Research summit. J Soc Work End Life Palliat Care 7 (2011), 291–299.
-
(2011)
J Soc Work End Life Palliat Care
, vol.7
, pp. 291-299
-
-
Csikai, E.L.1
-
215
-
-
84976631469
-
The spectrum of caregiving in palliative care for serious, advanced, rare diseases: key issues and research directions
-
Adams, LS, Miller, JL, Grady, PA, The spectrum of caregiving in palliative care for serious, advanced, rare diseases: key issues and research directions. J Palliat Med 19 (2016), 698–705.
-
(2016)
J Palliat Med
, vol.19
, pp. 698-705
-
-
Adams, L.S.1
Miller, J.L.2
Grady, P.A.3
-
216
-
-
84895905278
-
End-of-life care—what do cancer patients want?
-
Khan, SA, Gomes, B, Higginson, IJ, End-of-life care—what do cancer patients want?. Nat Rev Clin Oncol 11 (2014), 100–108.
-
(2014)
Nat Rev Clin Oncol
, vol.11
, pp. 100-108
-
-
Khan, S.A.1
Gomes, B.2
Higginson, I.J.3
-
217
-
-
84986321970
-
Using routine data to improve palliative and end of life care
-
Davies, JM, Gao, W, Sleeman, KE, Using routine data to improve palliative and end of life care. BMJ Support Palliat Care 6 (2016), 257–262.
-
(2016)
BMJ Support Palliat Care
, vol.6
, pp. 257-262
-
-
Davies, J.M.1
Gao, W.2
Sleeman, K.E.3
-
218
-
-
83555172634
-
A pan-European survey of research in end-of-life cancer care
-
Sigurdardottir, KR, Haugen, DF, Bausewein, C, et al., Project PRISMA. A pan-European survey of research in end-of-life cancer care. Support Care Cancer 20 (2012), 39–48.
-
(2012)
Support Care Cancer
, vol.20
, pp. 39-48
-
-
Sigurdardottir, K.R.1
Haugen, D.F.2
Bausewein, C.3
-
219
-
-
85021843310
-
Foundation funding for palliative and end-of-life care
-
Prina, LL, Foundation funding for palliative and end-of-life care. Health Aff (Millwood) 36 (2017), 1340–1342.
-
(2017)
Health Aff (Millwood)
, vol.36
, pp. 1340-1342
-
-
Prina, L.L.1
-
221
-
-
79959961573
-
The role of local therapy in the management of lung and liver oligometastases
-
Lo, SS, Moffatt-Bruce, SD, Dawson, LA, et al. The role of local therapy in the management of lung and liver oligometastases. Nature Rev Clin Oncol 8 (2011), 405–416.
-
(2011)
Nature Rev Clin Oncol
, vol.8
, pp. 405-416
-
-
Lo, S.S.1
Moffatt-Bruce, S.D.2
Dawson, L.A.3
-
222
-
-
63749100778
-
Multi–institutional phase I/II trial of stereotactic body radiation therapy for liver metastases
-
Rusthoven, KE, Kavanagh, BD, Cardenes, H, et al. Multi–institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27 (2009), 1572–1578.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1572-1578
-
-
Rusthoven, K.E.1
Kavanagh, B.D.2
Cardenes, H.3
-
223
-
-
63749100778
-
Multi–institutional phase I/II trial of stereotactic body radiation therapy for lung metastases
-
Rusthoven, KE, Kavanagh, BD, Burri, SH, et al. Multi–institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27 (2009), 1579–1584.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1579-1584
-
-
Rusthoven, K.E.1
Kavanagh, B.D.2
Burri, S.H.3
-
224
-
-
3242734176
-
Phase I clinical evaluation of near-simultaneous computed tomographic image–guided stereotactic body radiotherapy for spinal metastases
-
Chang, EL, Shiu, AS, Lii, MF, et al. Phase I clinical evaluation of near-simultaneous computed tomographic image–guided stereotactic body radiotherapy for spinal metastases. Int J Radiat Oncol Biol Phys 59 (2004), 1288–1294.
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.59
, pp. 1288-1294
-
-
Chang, E.L.1
Shiu, A.S.2
Lii, M.F.3
-
225
-
-
84862827663
-
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial
-
Wang, XS, Rhines, LD, Shiu, AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trial. Lancet Oncol 13 (2012), 395–402.
-
(2012)
Lancet Oncol
, vol.13
, pp. 395-402
-
-
Wang, X.S.1
Rhines, L.D.2
Shiu, A.S.3
-
226
-
-
84896699065
-
RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1–3) spine metastases: phase 2 results
-
Ryu, S, Pugh, SL, Gerszten, PC, et al. RTOG 0631 phase 2/3 study of image guided stereotactic radiosurgery for localized (1–3) spine metastases: phase 2 results. Pract Radiat Oncol 4 (2014), 76–81.
-
(2014)
Pract Radiat Oncol
, vol.4
, pp. 76-81
-
-
Ryu, S.1
Pugh, S.L.2
Gerszten, P.C.3
-
227
-
-
84912066879
-
Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer
-
Iyengar, P, Kavanagh, BD, Wardak, Z, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32 (2014), 3824–3830.
-
(2014)
J Clin Oncol
, vol.32
, pp. 3824-3830
-
-
Iyengar, P.1
Kavanagh, B.D.2
Wardak, Z.3
-
228
-
-
85002622789
-
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first–line systemic therapy: a multicentre, randomised, controlled, phase 2 study
-
Gomez, DR, Blumenschein, GR, Lee, JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first–line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncology 17 (2016), 1672–1682.
-
(2016)
Lancet Oncology
, vol.17
, pp. 1672-1682
-
-
Gomez, D.R.1
Blumenschein, G.R.2
Lee, J.J.3
-
229
-
-
32144433159
-
Radiotherapy plus cetuximab for squamous–cell carcinoma of the head and neck
-
Bonner, JA, Harari, PM, Giralt, J, et al. Radiotherapy plus cetuximab for squamous–cell carcinoma of the head and neck. N Engl J Med 354 (2006), 567–578.
-
(2006)
N Engl J Med
, vol.354
, pp. 567-578
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
-
230
-
-
84961992269
-
STAT1 induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients
-
Srivastava, RM, Trivedi, S, Concha-Benavente, F, et al. STAT1 induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients. Cancer Immunol Res 3 (2015), 936–945.
-
(2015)
Cancer Immunol Res
, vol.3
, pp. 936-945
-
-
Srivastava, R.M.1
Trivedi, S.2
Concha-Benavente, F.3
-
231
-
-
84907010373
-
Interaction of radiation therapy with molecular targeted agents
-
Morris, ZS, Harari, PM, Interaction of radiation therapy with molecular targeted agents. J Clin Oncol 32 (2014), 2886–2893.
-
(2014)
J Clin Oncol
, vol.32
, pp. 2886-2893
-
-
Morris, Z.S.1
Harari, P.M.2
-
232
-
-
84959148338
-
Science in focus: combining radiotherapy with inhibitors of the DNA damage response
-
Chalmers, AJ, Science in focus: combining radiotherapy with inhibitors of the DNA damage response. Clin Oncol (R Coll Radiol) 5 (2016), 279–282.
-
(2016)
Clin Oncol (R Coll Radiol)
, vol.5
, pp. 279-282
-
-
Chalmers, A.J.1
-
233
-
-
84857815877
-
Immunologic correlates of the abscopal effect in a patient with melanoma
-
Postow, MA, Callahan, MK, Barker, CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
-
(2012)
N Engl J Med
, vol.366
, pp. 925-931
-
-
Postow, M.A.1
Callahan, M.K.2
Barker, C.A.3
-
234
-
-
84861398744
-
Abscopal effect in a patient with melanoma
-
Hiniker, SM, Chen, DS, Knox, SJ, Abscopal effect in a patient with melanoma. N Engl J Med, 366, 2012, 2035.
-
(2012)
N Engl J Med
, vol.366
, pp. 2035
-
-
Hiniker, S.M.1
Chen, D.S.2
Knox, S.J.3
-
235
-
-
84872202826
-
The abscopal effect associated with a systemic antimelanoma immune response
-
Stamell, EF, Wolchok, JD, Gnjatic, S, et al. The abscopal effect associated with a systemic antimelanoma immune response. Int J Radiat Oncol Biol Phys 85 (2013), 293–295.
-
(2013)
Int J Radiat Oncol Biol Phys
, vol.85
, pp. 293-295
-
-
Stamell, E.F.1
Wolchok, J.D.2
Gnjatic, S.3
-
236
-
-
84862124594
-
Phase 1 study of stereotactic body radiotherapy and interleukin–2: tumor and immunological responses
-
Seung, SK, Curti, BD, Crittenden, M, et al. Phase 1 study of stereotactic body radiotherapy and interleukin–2: tumor and immunological responses. Sci Transl Med, 4, 2012, 137ra74.
-
(2012)
Sci Transl Med
, vol.4
, pp. 137ra74
-
-
Seung, S.K.1
Curti, B.D.2
Crittenden, M.3
-
237
-
-
84875039618
-
Combining radiotherapy and cancer immunotherapy: a paradigm shift
-
Formenti, SC, Demaria, S, Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105 (2013), 256–265.
-
(2013)
J Natl Cancer Inst
, vol.105
, pp. 256-265
-
-
Formenti, S.C.1
Demaria, S.2
-
238
-
-
45449090985
-
Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity
-
Lugade, AA, Sorensen, EW, Gerber, SA, et al. Radiation-induced IFN-γ production within the tumor microenvironment influences antitumor immunity. J Immunol 180 (2008), 3132–3139.
-
(2008)
J Immunol
, vol.180
, pp. 3132-3139
-
-
Lugade, A.A.1
Sorensen, E.W.2
Gerber, S.A.3
-
239
-
-
51549088023
-
Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells
-
Matsumura, S, Wang, B, Kawashima, N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181 (2008), 3099–3107.
-
(2008)
J Immunol
, vol.181
, pp. 3099-3107
-
-
Matsumura, S.1
Wang, B.2
Kawashima, N.3
-
240
-
-
0037942745
-
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
-
Chakraborty, M, Abrams, SI, Camphausen, K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol 170 (2003), 6338–6347.
-
(2003)
J Immunol
, vol.170
, pp. 6338-6347
-
-
Chakraborty, M.1
Abrams, S.I.2
Camphausen, K.3
-
241
-
-
84857542033
-
Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways
-
Ifeadi, V, Garnett–Benson, C, Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS One, 7, 2012, e31762.
-
(2012)
PLoS One
, vol.7
, pp. e31762
-
-
Ifeadi, V.1
Garnett-Benson, C.2
-
242
-
-
7444258053
-
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes
-
Garnett, CT, Palena, C, Chakarborty, M, Tsang, KY, Schlom, J, Hodge, JW, Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64 (2004), 7985–7994.
-
(2004)
Cancer Res
, vol.64
, pp. 7985-7994
-
-
Garnett, C.T.1
Palena, C.2
Chakarborty, M.3
Tsang, K.Y.4
Schlom, J.5
Hodge, J.W.6
-
243
-
-
33646704729
-
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
-
Reits, EA, Hodge, JW, Herberts, CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203 (2006), 1259–1271.
-
(2006)
J Exp Med
, vol.203
, pp. 1259-1271
-
-
Reits, E.A.1
Hodge, J.W.2
Herberts, C.A.3
-
244
-
-
0034103794
-
γ-ray irradiation induces B7. 1 expression in myeloid leukaemic cells
-
Vereecque, R, Buffenoir, G, Gonzalez, R, et al. γ-ray irradiation induces B7. 1 expression in myeloid leukaemic cells. Br J Haematol 108 (2000), 825–831.
-
(2000)
Br J Haematol
, vol.108
, pp. 825-831
-
-
Vereecque, R.1
Buffenoir, G.2
Gonzalez, R.3
-
245
-
-
24144443517
-
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
-
Gasser, S, Orsulic, S, Brown, EJ, Raulet, DH, The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005), 1186–1190.
-
(2005)
Nature
, vol.436
, pp. 1186-1190
-
-
Gasser, S.1
Orsulic, S.2
Brown, E.J.3
Raulet, D.H.4
-
246
-
-
33750725084
-
Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation
-
Kim, J, Son, Y, Park, S, et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med, 38, 2006, 474.
-
(2006)
Exp Mol Med
, vol.38
, pp. 474
-
-
Kim, J.1
Son, Y.2
Park, S.3
-
247
-
-
84929366910
-
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
-
Vanpouille-Box, C, Diamond, JM, Pilones, KA, et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res 75 (2015), 2232–2242.
-
(2015)
Cancer Res
, vol.75
, pp. 2232-2242
-
-
Vanpouille-Box, C.1
Diamond, J.M.2
Pilones, K.A.3
-
248
-
-
34247844643
-
Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth
-
Tsai, CS, Chen, FH, Wang, CC, et al. Macrophages from irradiated tumors express higher levels of iNOS, arginase-I and COX-2, and promote tumor growth. Int J Radiat Oncol Biol Phys 68 (2007), 499–507.
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.68
, pp. 499-507
-
-
Tsai, C.S.1
Chen, F.H.2
Wang, C.C.3
-
249
-
-
84875024405
-
Irradiation promotes an m2 macrophage phenotype in tumor hypoxia
-
Chiang, CS, Fu, SY, Wang, SC, et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol, 2, 2012, 89.
-
(2012)
Front Oncol
, vol.2
, pp. 89
-
-
Chiang, C.S.1
Fu, S.Y.2
Wang, S.C.3
-
250
-
-
84908691423
-
Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response
-
Kuo, P, Bratman, SV, Shultz, DB, et al. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. Clin Cancer Res 20 (2014), 5558–5569.
-
(2014)
Clin Cancer Res
, vol.20
, pp. 5558-5569
-
-
Kuo, P.1
Bratman, S.V.2
Shultz, D.B.3
-
251
-
-
84893876109
-
Irradiation and anti–PD–L1 treatment synergistically promote antitumor immunity in mice
-
Deng, L, Liang, H, Burnette, B, et al. Irradiation and anti–PD–L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124 (2014), 687–695.
-
(2014)
J Clin Invest
, vol.124
, pp. 687-695
-
-
Deng, L.1
Liang, H.2
Burnette, B.3
-
252
-
-
0034305965
-
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
-
Brizel, DM, Wasserman, TH, Henke, M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 (2000), 3339–3345.
-
(2000)
J Clin Oncol
, vol.18
, pp. 3339-3345
-
-
Brizel, D.M.1
Wasserman, T.H.2
Henke, M.3
-
253
-
-
84901227921
-
PHD inhibition mitigates and protects against radiation–induced gastrointestinal toxicity via HIF2
-
Taniguchi, CM, Miao, YR, Diep, AN, et al. PHD inhibition mitigates and protects against radiation–induced gastrointestinal toxicity via HIF2. Sci Transl Med, 6, 2014, 236ra64.
-
(2014)
Sci Transl Med
, vol.6
, pp. 236ra64
-
-
Taniguchi, C.M.1
Miao, Y.R.2
Diep, A.N.3
-
254
-
-
84902485527
-
Stem cell therapies for the treatment of radiation–induced normal tissue side effects
-
Benderitter, M, Caviggioli, F, Chapel, A, et al. Stem cell therapies for the treatment of radiation–induced normal tissue side effects. Antioxid Redox Signal 21 (2014), 338–355.
-
(2014)
Antioxid Redox Signal
, vol.21
, pp. 338-355
-
-
Benderitter, M.1
Caviggioli, F.2
Chapel, A.3
-
255
-
-
84904061727
-
Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA
-
Haber, DA, Velculescu, VE, Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4 (2014), 650–661.
-
(2014)
Cancer Discov
, vol.4
, pp. 650-661
-
-
Haber, D.A.1
Velculescu, V.E.2
-
256
-
-
84941551429
-
Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA
-
Chaudhuri, AA, Binkley, MS, Osmundson, EC, Alizadeh, AA, Diehn, M, Predicting radiotherapy responses and treatment outcomes through analysis of circulating tumor DNA. Semin Radiat Oncol 25 (2015), 305–312.
-
(2015)
Semin Radiat Oncol
, vol.25
, pp. 305-312
-
-
Chaudhuri, A.A.1
Binkley, M.S.2
Osmundson, E.C.3
Alizadeh, A.A.4
Diehn, M.5
-
257
-
-
84877099043
-
An international collaboration to harmonize the quantitative plasma Epstein–Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma
-
Le, QT, Zhang, Q, Cao, H, et al. An international collaboration to harmonize the quantitative plasma Epstein–Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res 19 (2013), 2208–2215.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 2208-2215
-
-
Le, Q.T.1
Zhang, Q.2
Cao, H.3
-
258
-
-
84903218109
-
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
-
Newman, AM, Bratman, SV, To, J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Med 20 (2014), 548–554.
-
(2014)
Nature Med
, vol.20
, pp. 548-554
-
-
Newman, A.M.1
Bratman, S.V.2
To, J.3
-
259
-
-
85009404026
-
Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance
-
Jeong, Y, Hoang, NT, Lovejoy, A, et al. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discov 7 (2017), 86–101.
-
(2017)
Cancer Discov
, vol.7
, pp. 86-101
-
-
Jeong, Y.1
Hoang, N.T.2
Lovejoy, A.3
-
260
-
-
85008193431
-
A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort–based study
-
Scott, JG, Berglund, A, Schell, MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort–based study. Lancet Oncol 18 (2016), 202–211.
-
(2016)
Lancet Oncol
, vol.18
, pp. 202-211
-
-
Scott, J.G.1
Berglund, A.2
Schell, M.J.3
-
261
-
-
84925348152
-
Lung texture in serial thoracic computed tomography scans: correlation of radiomics–based features with radiation therapy dose and radiation pneumonitis development
-
Cunliffe, A, Armato, SG, Castillo, R, et al. Lung texture in serial thoracic computed tomography scans: correlation of radiomics–based features with radiation therapy dose and radiation pneumonitis development. Int J Radiat Oncol Biol Phys 91 (2015), 1048–1056.
-
(2015)
Int J Radiat Oncol Biol Phys
, vol.91
, pp. 1048-1056
-
-
Cunliffe, A.1
Armato, S.G.2
Castillo, R.3
-
262
-
-
84898665704
-
Comparison of 4–dimensional computed tomography ventilation with nuclear medicine ventilation–perfusion imaging: a clinical validation study
-
Vinogradskiy, Y, Koo, PJ, Castillo, R, et al. Comparison of 4–dimensional computed tomography ventilation with nuclear medicine ventilation–perfusion imaging: a clinical validation study. Int J Radiat Oncol Biol Phys 89 (2014), 199–205.
-
(2014)
Int J Radiat Oncol Biol Phys
, vol.89
, pp. 199-205
-
-
Vinogradskiy, Y.1
Koo, P.J.2
Castillo, R.3
-
263
-
-
84975297433
-
Regional lung function profiles of stage I and III lung cancer patients: an evaluation for functional avoidance radiation therapy
-
Vinogradskiy, Y, Schubert, L, Diot, Q, et al. Regional lung function profiles of stage I and III lung cancer patients: an evaluation for functional avoidance radiation therapy. Int J Radiat Oncol Biol Phys 95 (2016), 1273–1280.
-
(2016)
Int J Radiat Oncol Biol Phys
, vol.95
, pp. 1273-1280
-
-
Vinogradskiy, Y.1
Schubert, L.2
Diot, Q.3
-
264
-
-
84889884752
-
Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma
-
Mailhot Vega, RB, Kim, J, Bussière, M, et al. Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer 119 (2013), 4299–4307.
-
(2013)
Cancer
, vol.119
, pp. 4299-4307
-
-
Mailhot Vega, R.B.1
Kim, J.2
Bussière, M.3
-
265
-
-
84960495145
-
Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study
-
Yock, TI, Yeap, BY, Ebb, DH, et al. Long-term toxic effects of proton radiotherapy for paediatric medulloblastoma: a phase 2 single-arm study. Lancet Oncol 17 (2016), 287–298.
-
(2016)
Lancet Oncol
, vol.17
, pp. 287-298
-
-
Yock, T.I.1
Yeap, B.Y.2
Ebb, D.H.3
-
266
-
-
84951850596
-
Clinical outcomes among children with standard–risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival
-
Eaton, BR, Esiashvili, N, Kim, S, et al. Clinical outcomes among children with standard–risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival. Int J Radiat Oncol Biol Phys 94 (2016), 133–138.
-
(2016)
Int J Radiat Oncol Biol Phys
, vol.94
, pp. 133-138
-
-
Eaton, B.R.1
Esiashvili, N.2
Kim, S.3
-
267
-
-
69249223061
-
On the clinical spatial resolution achievable with protons and heavier charged particle radiotherapy beams
-
Andreo, P, On the clinical spatial resolution achievable with protons and heavier charged particle radiotherapy beams. Phys Med Biol, 54, 2009, N205.
-
(2009)
Phys Med Biol
, vol.54
, pp. N205
-
-
Andreo, P.1
-
268
-
-
85027976702
-
Humbling advances in technology: protons, brainstem necrosis, and the self-driving car
-
MacDonald, SM, Laack, NN, Terezakis, S, Humbling advances in technology: protons, brainstem necrosis, and the self-driving car. Int J Radiat Oncol Biol Phys, 97, 2017, 216.
-
(2017)
Int J Radiat Oncol Biol Phys
, vol.97
, pp. 216
-
-
MacDonald, S.M.1
Laack, N.N.2
Terezakis, S.3
-
269
-
-
84907010602
-
Promise and pitfalls of heavy-particle therapy
-
Mitin, T, Zietman, AL, Promise and pitfalls of heavy-particle therapy. J Clin Oncol 32 (2014), 2855–2863.
-
(2014)
J Clin Oncol
, vol.32
, pp. 2855-2863
-
-
Mitin, T.1
Zietman, A.L.2
-
270
-
-
84982816401
-
Carbon ion irradiation withstands cancer stem cells' migration/invasion process in head and neck squamous cell carcinoma (HNSCC)
-
Moncharmont, C, Guy, JB, Wozny, AS, et al. Carbon ion irradiation withstands cancer stem cells' migration/invasion process in head and neck squamous cell carcinoma (HNSCC). Oncotarget, 7, 2016, 47738.
-
(2016)
Oncotarget
, vol.7
, pp. 47738
-
-
Moncharmont, C.1
Guy, J.B.2
Wozny, A.S.3
-
271
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker, C, Nilsson, S, Heinrich, D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 (2013), 213–223.
-
(2013)
N Engl J Med
, vol.369
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
-
273
-
-
84929910660
-
Radioimmunotherapy of human tumours
-
Larson, SM, Carrasquillo, JA, Cheung, NK, Press, OW, Radioimmunotherapy of human tumours. Nat Rev Cancer 15 (2015), 347–360.
-
(2015)
Nat Rev Cancer
, vol.15
, pp. 347-360
-
-
Larson, S.M.1
Carrasquillo, J.A.2
Cheung, N.K.3
Press, O.W.4
-
274
-
-
84958750599
-
Quantitative imaging in cancer clinical trials
-
Yankeelov, TE, Mankoff, DA, Schwartz, LH, et al. Quantitative imaging in cancer clinical trials. Clin Cancer Res 22 (2016), 284–290.
-
(2016)
Clin Cancer Res
, vol.22
, pp. 284-290
-
-
Yankeelov, T.E.1
Mankoff, D.A.2
Schwartz, L.H.3
-
275
-
-
28144449723
-
The progress and promise of molecular imaging probes in oncologic drug development
-
Kelloff, GJ, Krohn, KA, Larson, SM, et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11 (2005), 7967–7985.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7967-7985
-
-
Kelloff, G.J.1
Krohn, K.A.2
Larson, S.M.3
-
276
-
-
84988808393
-
Imaging approaches to optimize molecular therapies
-
Weissleder, R, Schwaiger, MC, Gambhir, SS, Hricak, H, Imaging approaches to optimize molecular therapies. Sci Transl Med, 8, 2016, 355ps16.
-
(2016)
Sci Transl Med
, vol.8
, pp. 355ps16
-
-
Weissleder, R.1
Schwaiger, M.C.2
Gambhir, S.S.3
Hricak, H.4
-
277
-
-
85020104379
-
Making molecular imaging a clinical tool for precision oncology: a review
-
Mankoff, DA, Farwell, MD, Clark, AS, Pryma, DA, Making molecular imaging a clinical tool for precision oncology: a review. JAMA Oncol 3 (2016), 695–701.
-
(2016)
JAMA Oncol
, vol.3
, pp. 695-701
-
-
Mankoff, D.A.1
Farwell, M.D.2
Clark, A.S.3
Pryma, D.A.4
-
278
-
-
77951474500
-
89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer
-
89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87 (2010), 586–592.
-
(2010)
Clin Pharmacol Ther
, vol.87
, pp. 586-592
-
-
Dijkers, E.C.1
Oude Munnink, T.H.2
Kosterink, J.G.3
-
279
-
-
40449093680
-
Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol
-
Peterson, LM, Mankoff, DA, Lawton, T, et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49 (2008), 367–374.
-
(2008)
J Nucl Med
, vol.49
, pp. 367-374
-
-
Peterson, L.M.1
Mankoff, D.A.2
Lawton, T.3
-
281
-
-
33745545477
-
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
-
Linden, HM, Stekhova, SA, Link, JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol 24 (2006), 2793–2799.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2793-2799
-
-
Linden, H.M.1
Stekhova, S.A.2
Link, J.M.3
-
282
-
-
0035367157
-
Metabolic flare: indicator of hormone responsiveness in advanced breast cancer
-
Mortimer, JE, Dehdashti, F, Siegel, BA, Trinkaus, K, Katzenellenbogen, JA, Welch, MJ, Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19 (2001), 2797–2803.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2797-2803
-
-
Mortimer, J.E.1
Dehdashti, F.2
Siegel, B.A.3
Trinkaus, K.4
Katzenellenbogen, J.A.5
Welch, M.J.6
-
283
-
-
84890308316
-
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO
-
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med 54 (2013), 1862–1868.
-
(2013)
J Nucl Med
, vol.54
, pp. 1862-1868
-
-
Gebhart, G.1
Gamez, C.2
Holmes, E.3
-
284
-
-
84879919355
-
18F-FDG PET in Hodgkin lymphoma: would PET–adapted clinical trials lead to a paradigm shift?
-
18F-FDG PET in Hodgkin lymphoma: would PET–adapted clinical trials lead to a paradigm shift?. J Nucl Med 54 (2013), 1082–1093.
-
(2013)
J Nucl Med
, vol.54
, pp. 1082-1093
-
-
Kostakoglu, L.1
Gallamini, A.2
-
286
-
-
33745955010
-
Positron emission tomography as an imaging biomarker
-
Weber, WA, Positron emission tomography as an imaging biomarker. J Clin Oncol 24 (2006), 3282–3292.
-
(2006)
J Clin Oncol
, vol.24
, pp. 3282-3292
-
-
Weber, W.A.1
-
287
-
-
84055222053
-
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel
-
Contractor, KB, Kenny, LM, Stebbing, J, et al. [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res 17 (2011), 7664–7672.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 7664-7672
-
-
Contractor, K.B.1
Kenny, L.M.2
Stebbing, J.3
-
288
-
-
58149337441
-
18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung
-
18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 14 (2008), 7423–7429.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7423-7429
-
-
Sohn, H.J.1
Yang, Y.J.2
Ryu, J.S.3
-
289
-
-
84964617575
-
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
-
Gebhart, G, Lamberts, LE, Wimana, Z, et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. Ann Oncol 27 (2016), 619–624.
-
(2016)
Ann Oncol
, vol.27
, pp. 619-624
-
-
Gebhart, G.1
Lamberts, L.E.2
Wimana, Z.3
-
291
-
-
84946573144
-
A phase ii study of 3'–Deoxy–3'–18F–fluorothymidine PET in the assessment of early response of breast cancer to neoadjuvant chemotherapy: results from ACRIN 6688
-
Kostakoglu, L, Duan, F, Idowu, MO, et al. A phase ii study of 3'–Deoxy–3'–18F–fluorothymidine PET in the assessment of early response of breast cancer to neoadjuvant chemotherapy: results from ACRIN 6688. J Nucl Med 56 (2015), 1681–1689.
-
(2015)
J Nucl Med
, vol.56
, pp. 1681-1689
-
-
Kostakoglu, L.1
Duan, F.2
Idowu, M.O.3
-
292
-
-
84940449844
-
Imaging innate immune responses at tumour initiation: new insights from fish and flies
-
Feng, Y, Martin, P, Imaging innate immune responses at tumour initiation: new insights from fish and flies. Nat Rev Cancer 15 (2015), 556–562.
-
(2015)
Nat Rev Cancer
, vol.15
, pp. 556-562
-
-
Feng, Y.1
Martin, P.2
-
293
-
-
84869380716
-
Immunology beats cancer: a blueprint for successful translation
-
Pardoll, DM, Immunology beats cancer: a blueprint for successful translation. Nat Immunol 13 (2012), 1129–1132.
-
(2012)
Nat Immunol
, vol.13
, pp. 1129-1132
-
-
Pardoll, D.M.1
-
294
-
-
84881084626
-
Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma
-
Gilles, R, de Geus–Oei, LF, Mulders, PF, Oyen, WJ, Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma. World J Urol 31 (2013), 841–846.
-
(2013)
World J Urol
, vol.31
, pp. 841-846
-
-
Gilles, R.1
de Geus–Oei, L.F.2
Mulders, P.F.3
Oyen, W.J.4
-
295
-
-
44849103991
-
PET imaging of cancer immunotherapy
-
Tumeh, PC, Radu, CG, Ribas, A, PET imaging of cancer immunotherapy. J Nucl Med 49 (2008), 865–868.
-
(2008)
J Nucl Med
, vol.49
, pp. 865-868
-
-
Tumeh, P.C.1
Radu, C.G.2
Ribas, A.3
-
296
-
-
85014322386
-
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
-
Seymour, L, Bogaerts, J, Perrone, A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18 (2017), e143–e152.
-
(2017)
Lancet Oncol
, vol.18
, pp. e143-e152
-
-
Seymour, L.1
Bogaerts, J.2
Perrone, A.3
-
297
-
-
66149139452
-
From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors
-
Wahl, RL, Jacene, H, Kasamon, Y, Lodge, MA, From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:suppl 1 (2009), 122S–150S.
-
(2009)
J Nucl Med
, vol.50
, pp. 122S-150S
-
-
Wahl, R.L.1
Jacene, H.2
Kasamon, Y.3
Lodge, M.A.4
-
298
-
-
84928917822
-
Pooled Analysis of Long–Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
-
Schadendorf, D, Hodi, FS, Robert, C, Weber, JS, Margolin, K, Hamid, O, et al. Pooled Analysis of Long–Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 33 (2015), 1889–1894.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1889-1894
-
-
Schadendorf, D.1
Hodi, F.S.2
Robert, C.3
Weber, J.S.4
Margolin, K.5
Hamid, O.6
-
299
-
-
85009383088
-
Rapid PD–L1 detection in tumors with PET using a highly specific peptide
-
Chatterjee, S, Lesniak, WG, Miller, MS, et al. Rapid PD–L1 detection in tumors with PET using a highly specific peptide. Biochem Biophys Res Commun 483 (2017), 258–263.
-
(2017)
Biochem Biophys Res Commun
, vol.483
, pp. 258-263
-
-
Chatterjee, S.1
Lesniak, W.G.2
Miller, M.S.3
-
300
-
-
84898973055
-
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
-
Topalian, SL, Sznol, M, McDermott, DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32 (2014), 1020–1030.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1020-1030
-
-
Topalian, S.L.1
Sznol, M.2
McDermott, D.F.3
-
301
-
-
85016924502
-
The FDA, Juno Therapeutics, and the ethical imperative of transparency
-
Hey, SP, Kesselheim, AS, The FDA, Juno Therapeutics, and the ethical imperative of transparency. BMJ, 354, 2016, i4435.
-
(2016)
BMJ
, vol.354
, pp. i4435
-
-
Hey, S.P.1
Kesselheim, A.S.2
-
302
-
-
84975817715
-
imaging biomarkers in immunotherapy
-
Juergens, RA, Zukotynski, KA, Singnurkar, A, Snider, DP, Valliant, JF, Gulenchyn, KY, imaging biomarkers in immunotherapy. Biomark Cancer 8:suppl 2 (2016), 1–13.
-
(2016)
Biomark Cancer
, vol.8
, pp. 1-13
-
-
Juergens, R.A.1
Zukotynski, K.A.2
Singnurkar, A.3
Snider, D.P.4
Valliant, J.F.5
Gulenchyn, K.Y.6
-
303
-
-
84991372950
-
Molecular imaging of immunotherapy targets in cancer
-
Ehlerding, EB, England, CG, McNeel, DG, Cai, W, Molecular imaging of immunotherapy targets in cancer. J Nucl Med 57 (2016), 1487–1492.
-
(2016)
J Nucl Med
, vol.57
, pp. 1487-1492
-
-
Ehlerding, E.B.1
England, C.G.2
McNeel, D.G.3
Cai, W.4
-
304
-
-
0037022647
-
Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography
-
Adonai, N, Nguyen, KN, Walsh, J, et al. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci USA 99 (2002), 3030–3035.
-
(2002)
Proc Natl Acad Sci USA
, vol.99
, pp. 3030-3035
-
-
Adonai, N.1
Nguyen, K.N.2
Walsh, J.3
-
305
-
-
33646058046
-
Monitoring the antitumor response of naive and memory CD8 T cells in RAG1-/- mice by positron-emission tomography
-
Su, H, Chang, DS, Gambhir, SS, Braun, J, Monitoring the antitumor response of naive and memory CD8 T cells in RAG1-/- mice by positron-emission tomography. J Immunol 176 (2006), 4459–4467.
-
(2006)
J Immunol
, vol.176
, pp. 4459-4467
-
-
Su, H.1
Chang, D.S.2
Gambhir, S.S.3
Braun, J.4
-
306
-
-
84973125305
-
Imaging of sleeping beauty–modified CD19–specific T cells Expressing HSV1–thymidine kinase by positron emission tomography
-
Najjar, AM, Manuri, PR, Olivares, S, et al. Imaging of sleeping beauty–modified CD19–specific T cells Expressing HSV1–thymidine kinase by positron emission tomography. Mol Imaging Biol 18 (2016), 838–848.
-
(2016)
Mol Imaging Biol
, vol.18
, pp. 838-848
-
-
Najjar, A.M.1
Manuri, P.R.2
Olivares, S.3
-
307
-
-
84929323415
-
Tracking of dendritic cell migration into lymph nodes using molecular imaging with sodium iodide symporter and enhanced firefly luciferase genes
-
Lee, HW, Yoon, SY, Singh, TD, et al. Tracking of dendritic cell migration into lymph nodes using molecular imaging with sodium iodide symporter and enhanced firefly luciferase genes. Sci Rep, 5, 2015, 9865.
-
(2015)
Sci Rep
, vol.5
, pp. 9865
-
-
Lee, H.W.1
Yoon, S.Y.2
Singh, T.D.3
-
308
-
-
85010451084
-
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
-
Keu, KV, Witney, TH, Yaghoubi, S, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med, 9, 2017, eaag2196.
-
(2017)
Sci Transl Med
, vol.9
, pp. eaag2196
-
-
Keu, K.V.1
Witney, T.H.2
Yaghoubi, S.3
-
309
-
-
84961666341
-
A humanized antibody for imaging immune checkpoint ligand PD–L1 expression in tumors
-
Chatterjee, S, Lesniak, WG, Gabrielson, M, et al. A humanized antibody for imaging immune checkpoint ligand PD–L1 expression in tumors. Oncotarget 7 (2016), 10215–10227.
-
(2016)
Oncotarget
, vol.7
, pp. 10215-10227
-
-
Chatterjee, S.1
Lesniak, W.G.2
Gabrielson, M.3
-
310
-
-
84945555686
-
Novel radiotracer for immunoPET imaging of PD–1 checkpoint expression on tumor infiltrating lymphocytes
-
Natarajan, A, Mayer, AT, Xu, L, Reeves, RE, Gano, J, Gambhir, SS, Novel radiotracer for immunoPET imaging of PD–1 checkpoint expression on tumor infiltrating lymphocytes. Bioconjug Chem 26 (2015), 2062–2069.
-
(2015)
Bioconjug Chem
, vol.26
, pp. 2062-2069
-
-
Natarajan, A.1
Mayer, A.T.2
Xu, L.3
Reeves, R.E.4
Gano, J.5
Gambhir, S.S.6
-
311
-
-
84929191608
-
Noninvasive imaging of immune responses
-
Rashidian, M, Keliher, EJ, Bilate, AM, et al. Noninvasive imaging of immune responses. Proc Natl Acad Sci USA 112 (2015), 6146–6151.
-
(2015)
Proc Natl Acad Sci USA
, vol.112
, pp. 6146-6151
-
-
Rashidian, M.1
Keliher, E.J.2
Bilate, A.M.3
-
312
-
-
84978654959
-
Immuno–PET imaging of engineered human T cells in tumors
-
Mall, S, Yusufi, N, Wagner, R, et al. Immuno–PET imaging of engineered human T cells in tumors. Cancer Res 76 (2016), 4113–4123.
-
(2016)
Cancer Res
, vol.76
, pp. 4113-4123
-
-
Mall, S.1
Yusufi, N.2
Wagner, R.3
-
313
-
-
84963631929
-
[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity
-
Kim, W, Le, TM, Wei, L, et al. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc Natl Acad Sci USA 113 (2016), 4027–4032.
-
(2016)
Proc Natl Acad Sci USA
, vol.113
, pp. 4027-4032
-
-
Kim, W.1
Le, T.M.2
Wei, L.3
-
314
-
-
84864545273
-
Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka Experience
-
Baum, RP, Kulkarni, HR, Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka Experience. Theranostics 2 (2012), 437–447.
-
(2012)
Theranostics
, vol.2
, pp. 437-447
-
-
Baum, R.P.1
Kulkarni, H.R.2
-
315
-
-
4644241347
-
Diagnostics + therapy=theranostics
-
Warner, S, Diagnostics + therapy=theranostics. The Scientist, Aug 30, 2004.
-
(2004)
The Scientist
-
-
Warner, S.1
-
316
-
-
84954239466
-
PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status theranostics
-
Lütje, S, Heskamp, S, Cornelissen, AS, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status theranostics. Theranostics 5 (2015), 1388–1401.
-
(2015)
Theranostics
, vol.5
, pp. 1388-1401
-
-
Lütje, S.1
Heskamp, S.2
Cornelissen, A.S.3
-
317
-
-
80054821668
-
Theranostics: combining imaging and therapy
-
Kelkar, SS, Reineke, TM, Theranostics: combining imaging and therapy. Bioconj Chem 22 (2011), 1879–1903.
-
(2011)
Bioconj Chem
, vol.22
, pp. 1879-1903
-
-
Kelkar, S.S.1
Reineke, T.M.2
-
318
-
-
84874029226
-
From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy
-
Alberti, C, From molecular imaging in preclinical/clinical oncology to theranostic applications in targeted tumor therapy. Eur Rev Med Pharmacol Sci 16 (2012), 1925–1933.
-
(2012)
Eur Rev Med Pharmacol Sci
, vol.16
, pp. 1925-1933
-
-
Alberti, C.1
-
319
-
-
84994852273
-
K. P. Nuclear medicine in cancer theranostics: beyond the target
-
Taieb, D, Hicks, RJ, K. P. Nuclear medicine in cancer theranostics: beyond the target. J Nucl Med 57 (2016), 1659–1660.
-
(2016)
J Nucl Med
, vol.57
, pp. 1659-1660
-
-
Taieb, D.1
Hicks, R.J.2
-
320
-
-
34447504408
-
Nuclear imaging in cancer theranostics
-
Del Vecchio, S, Zannetti, A, Fonti, R, Pace, I, Salvatore, M, Nuclear imaging in cancer theranostics. J Nucl Med Mol Imaging 51 (2007), 152–163.
-
(2007)
J Nucl Med Mol Imaging
, vol.51
, pp. 152-163
-
-
Del Vecchio, S.1
Zannetti, A.2
Fonti, R.3
Pace, I.4
Salvatore, M.5
-
321
-
-
84863460418
-
Dose escalation study of no–carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial
-
Matthay, KK, Weiss, B, Villablanca, JG, et al. Dose escalation study of no–carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med 53 (2012), 1155–1163.
-
(2012)
J Nucl Med
, vol.53
, pp. 1155-1163
-
-
Matthay, K.K.1
Weiss, B.2
Villablanca, J.G.3
-
322
-
-
52449111580
-
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with (90)Y-DOTATOC and (177)Lu-DOTATATE: the role of associated risk factors
-
Bodei, L, Cremonesi, M, Ferrari, M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with (90)Y-DOTATOC and (177)Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35 (2008), 1847–1856.
-
(2008)
Eur J Nucl Med Mol Imaging
, vol.35
, pp. 1847-1856
-
-
Bodei, L.1
Cremonesi, M.2
Ferrari, M.3
-
323
-
-
0034662510
-
Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience
-
Kaminski, MS, Estes, J, Zasadny, KR, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96 (2000), 1259–1266.
-
(2000)
Blood
, vol.96
, pp. 1259-1266
-
-
Kaminski, M.S.1
Estes, J.2
Zasadny, K.R.3
-
324
-
-
84859316607
-
Radioiodine: the classic theranostic agent
-
Silberstein, EB, Radioiodine: the classic theranostic agent. Semin Nucl Med 42 (2012), 164–170.
-
(2012)
Semin Nucl Med
, vol.42
, pp. 164-170
-
-
Silberstein, E.B.1
-
325
-
-
84973334406
-
Personalized medicine based on theranostic radioiodine molecular imaging for differentiated thyroid cancer
-
Ahn, B-C, Personalized medicine based on theranostic radioiodine molecular imaging for differentiated thyroid cancer. Biomed Res Int 1680464 (2016), 1–9.
-
(2016)
Biomed Res Int
, vol.1680464
, pp. 1-9
-
-
Ahn, B.-C.1
-
326
-
-
84859306773
-
Theranostics: evolution of the radiopharmaceutical meta–iodobenzylguanidine in endocrine tumors
-
Sisson, JC, Yanik, GA, Theranostics: evolution of the radiopharmaceutical meta–iodobenzylguanidine in endocrine tumors. Semin Nucl Med 42 (2012), 171–184.
-
(2012)
Semin Nucl Med
, vol.42
, pp. 171-184
-
-
Sisson, J.C.1
Yanik, G.A.2
-
327
-
-
84991320867
-
PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka Experience since 2013
-
Kulkarni, HR, Singh, A, Schuchardt, C, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka Experience since 2013. J Nucl Med 57 (2016), 97S–104S.
-
(2016)
J Nucl Med
, vol.57
, pp. 97S-104S
-
-
Kulkarni, H.R.1
Singh, A.2
Schuchardt, C.3
-
328
-
-
84958630177
-
90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease
-
90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med 57 (2016), 248–251.
-
(2016)
J Nucl Med
, vol.57
, pp. 248-251
-
-
Hermann, K.1
Schottelius, M.2
Lapa, C.3
-
329
-
-
85011961288
-
177Lu–NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology
-
177Lu–NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med 58 (2017), 293–299.
-
(2017)
J Nucl Med
, vol.58
, pp. 293-299
-
-
Dalm, S.U.1
Bakker, I.L.2
de Blois, E.3
-
330
-
-
0035100888
-
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework
-
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001), 89–95.
-
(2001)
Clin Pharmacol Ther
, vol.69
, pp. 89-95
-
-
-
331
-
-
79955010368
-
Early diagnosis of ovarian carcinoma: is a solution in sight?
-
Lutz, AM, Willmann, JK, Drescher, CW, et al. Early diagnosis of ovarian carcinoma: is a solution in sight?. Radiology 259 (2011), 329–345.
-
(2011)
Radiology
, vol.259
, pp. 329-345
-
-
Lutz, A.M.1
Willmann, J.K.2
Drescher, C.W.3
-
332
-
-
84905814502
-
Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer
-
Carlsson, A, Nair, VS, Luttgen, MS, et al. Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer. J Thorac Oncol 9 (2014), 1111–1119.
-
(2014)
J Thorac Oncol
, vol.9
, pp. 1111-1119
-
-
Carlsson, A.1
Nair, V.S.2
Luttgen, M.S.3
-
333
-
-
84879834620
-
An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer
-
Nair, VS, Keu, KV, Luttgen, MS, et al. An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PLoS One, 8, 2013, e67733.
-
(2013)
PLoS One
, vol.8
, pp. e67733
-
-
Nair, V.S.1
Keu, K.V.2
Luttgen, M.S.3
-
334
-
-
77956194618
-
18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer
-
De Giorgi, U, Mego, M, Rohren, EM, et al. 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. J Nucl Med 51 (2010), 1213–1218.
-
(2010)
J Nucl Med
, vol.51
, pp. 1213-1218
-
-
De Giorgi, U.1
Mego, M.2
Rohren, E.M.3
-
335
-
-
70249150745
-
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer
-
De Giorgi, U, Valero, V, Rohren, E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27 (2009), 3303–3311.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3303-3311
-
-
De Giorgi, U.1
Valero, V.2
Rohren, E.3
-
336
-
-
77949311998
-
Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer
-
De Giorgi, U, Valero, V, Rohren, E, et al. Circulating tumor cells and bone metastases as detected by FDG–PET/CT in patients with metastatic breast cancer. Ann Oncol 21 (2010), 33–39.
-
(2010)
Ann Oncol
, vol.21
, pp. 33-39
-
-
De Giorgi, U.1
Valero, V.2
Rohren, E.3
-
338
-
-
84897958983
-
Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging
-
Fahey, F, Zukotynski, K, Capala, J, Knight, N, Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. J Nucl Med 55 (2014), 337–348.
-
(2014)
J Nucl Med
, vol.55
, pp. 337-348
-
-
Fahey, F.1
Zukotynski, K.2
Capala, J.3
Knight, N.4
-
339
-
-
84936772103
-
Proceedings of the Second NCI–SNMMI workshop on targeted radionuclide therapy
-
Fahey, F, Zukotynski, K, Jadvar, H, Capala, J, Proceedings of the Second NCI–SNMMI workshop on targeted radionuclide therapy. J Nucl Med 56 (2015), 1119–1129.
-
(2015)
J Nucl Med
, vol.56
, pp. 1119-1129
-
-
Fahey, F.1
Zukotynski, K.2
Jadvar, H.3
Capala, J.4
-
340
-
-
84930373084
-
Summary of the UPICT protocol for 18F–FDG PET/CT imaging in oncology clinical trials
-
Graham, MM, Wahl, RL, Hoffman, JM, et al. Summary of the UPICT protocol for 18F–FDG PET/CT imaging in oncology clinical trials. J Nucl Med 56 (2015), 955–961.
-
(2015)
J Nucl Med
, vol.56
, pp. 955-961
-
-
Graham, M.M.1
Wahl, R.L.2
Hoffman, J.M.3
-
341
-
-
85042182900
-
Report of the Cancer Moonshot Task Force: executive summary
-
(accessed Oct 1, 2016).
-
Report of the Cancer Moonshot Task Force: executive summary. https://medium.com/cancer-moonshot/report-of-the-cancer-moonshot-task-force-executive-summary-e711f1845ec (accessed Oct 1, 2016).
-
-
-
-
342
-
-
77953632852
-
Surgical management and outcomes of colorectal cancer liver metastases
-
Morris, EJ, Forman, D, Thomas, JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 97 (2010), 1110–1118.
-
(2010)
Br J Surg
, vol.97
, pp. 1110-1118
-
-
Morris, E.J.1
Forman, D.2
Thomas, J.D.3
-
343
-
-
84966320804
-
Global curriculum in surgical oncology
-
Are, C, Berman, RS, Wyld, L, Cummings, C, Lecoq, C, Audisio, RA, Global curriculum in surgical oncology. Ann Surg Oncol 23 (2016), 1782–1795.
-
(2016)
Ann Surg Oncol
, vol.23
, pp. 1782-1795
-
-
Are, C.1
Berman, R.S.2
Wyld, L.3
Cummings, C.4
Lecoq, C.5
Audisio, R.A.6
-
344
-
-
84949639319
-
Image–guided surgery
-
Azagury, DE, Dua, MM, Barrese, JC, et al. Image–guided surgery. Curr Probl Surg 52 (2015), 476–520.
-
(2015)
Curr Probl Surg
, vol.52
, pp. 476-520
-
-
Azagury, D.E.1
Dua, M.M.2
Barrese, J.C.3
-
345
-
-
84942586191
-
Global cancer surgery: delivering safe, affordable, and timely cancer surgery
-
Sullivan, R, Alatise, OI, Anderson, BO, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol 16 (2015), 1193–1224.
-
(2015)
Lancet Oncol
, vol.16
, pp. 1193-1224
-
-
Sullivan, R.1
Alatise, O.I.2
Anderson, B.O.3
-
346
-
-
73249130298
-
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
-
Folprecht, G, Gruenberger, T, Bechstein, WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11 (2010), 38–47.
-
(2010)
Lancet Oncol
, vol.11
, pp. 38-47
-
-
Folprecht, G.1
Gruenberger, T.2
Bechstein, W.O.3
-
347
-
-
84989883694
-
FOLFIRI plus cetuximab in patients with liver–limited or non–liver–limited RAS wild–type metastatic colorectal cancer: a retrospective subgroup analysis of the CRYSTAL study
-
Köhne, CH, Poston, G, Folprecht, G, et al. FOLFIRI plus cetuximab in patients with liver–limited or non–liver–limited RAS wild–type metastatic colorectal cancer: a retrospective subgroup analysis of the CRYSTAL study. Eur J Surg Oncol 42 (2016), 1540–1547.
-
(2016)
Eur J Surg Oncol
, vol.42
, pp. 1540-1547
-
-
Köhne, C.H.1
Poston, G.2
Folprecht, G.3
-
348
-
-
84938304732
-
Big data for health
-
Andreu-Perez, J, Poon, CC, Merrifield, RD, Wong, ST, Yang, GZ, Big data for health. IEEE J Biomed Health Inform 19 (2015), 1193–1208.
-
(2015)
IEEE J Biomed Health Inform
, vol.19
, pp. 1193-1208
-
-
Andreu-Perez, J.1
Poon, C.C.2
Merrifield, R.D.3
Wong, S.T.4
Yang, G.Z.5
-
349
-
-
84929868382
-
Big data and biomedical informatics: a challenging opportunity
-
Bellazzi, R, Big data and biomedical informatics: a challenging opportunity. Yearb Med Inform 9 (2014), 8–13.
-
(2014)
Yearb Med Inform
, vol.9
, pp. 8-13
-
-
Bellazzi, R.1
-
350
-
-
85013080239
-
Big data analytics for genomic medicine
-
He, KY, Ge, D, He, MM, Big data analytics for genomic medicine. Int J Mol Sci, 18, 2017, 412.
-
(2017)
Int J Mol Sci
, vol.18
, pp. 412
-
-
He, K.Y.1
Ge, D.2
He, M.M.3
-
351
-
-
84901432298
-
Collaborative biomedicine in the age of big data: the case of cancer
-
Shaikh, AR, Butte, AJ, Schully, SD, Dalton, WS, Khoury, MJ, Hesse, BW, Collaborative biomedicine in the age of big data: the case of cancer. J Med Internet Res, 16, 2014, e101.
-
(2014)
J Med Internet Res
, vol.16
, pp. e101
-
-
Shaikh, A.R.1
Butte, A.J.2
Schully, S.D.3
Dalton, W.S.4
Khoury, M.J.5
Hesse, B.W.6
-
352
-
-
85013875756
-
Sharing big biomedical data
-
Toga, AW, Dinov, D, Sharing big biomedical data. J Big Data, 2, 2015, 7.
-
(2015)
J Big Data
, vol.2
, pp. 7
-
-
Toga, A.W.1
Dinov, D.2
-
353
-
-
78649359388
-
Big data: community cleverness required
-
Nature. Big data: community cleverness required. Nature, 455, 2008, 1.
-
(2008)
Nature
, vol.455
, pp. 1
-
-
-
354
-
-
84969976828
-
On big-data analytics in biomedical research
-
Chow, SC, Kong, Y, On big-data analytics in biomedical research. J Biomed Biostat, 6, 2015, 236.
-
(2015)
J Biomed Biostat
, vol.6
, pp. 236
-
-
Chow, S.C.1
Kong, Y.2
-
355
-
-
85099688310
-
Making big data useful for health care: a summary of the inaugural MIT Critical Data Conference
-
Badawi, O, Brennan, T, Celi, LA, et al. Making big data useful for health care: a summary of the inaugural MIT Critical Data Conference. JMIR Med Inform, 2, 2014, 2.
-
(2014)
JMIR Med Inform
, vol.2
, pp. 2
-
-
Badawi, O.1
Brennan, T.2
Celi, L.A.3
-
357
-
-
85042179068
-
NIH launches a united ecosystem for big data. 12 big data to knowledge centers of excellence funded
-
(accessed May 9, 2017).
-
Miller, K, NIH launches a united ecosystem for big data. 12 big data to knowledge centers of excellence funded. http://biomedicalcomputationreview.org/content/nih-launches-united-ecosystem-big-data, Jan 8, 2015 (accessed May 9, 2017).
-
(2015)
-
-
Miller, K.1
-
358
-
-
84886907976
-
Increasing access to the results of federally funded scientific research (memo)
-
(accessed May 9, 2017).
-
Executive Office of the President, Office of Science and Technology Policy. Increasing access to the results of federally funded scientific research (memo). https://obamawhitehouse.archives.gov/sites/default/files/microsites/ostp/ostp_public_access_memo_2013.pdf, Feb 22, 2013 (accessed May 9, 2017).
-
(2013)
-
-
-
359
-
-
85042174140
-
Project GENIE publicly releases large cancer genomic data set
-
(accessed May 9, 2017).
-
AACR. Project GENIE publicly releases large cancer genomic data set. http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=994#.WG5wXlPyu71, Jan 5, 2017 (accessed May 9, 2017).
-
(2017)
-
-
-
360
-
-
76649086980
-
National health expenditure fact sheet
-
(accessed May 23, 2017).
-
US Centers for Medicare & Medicaid Services. National health expenditure fact sheet. https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/nationalhealthexpenddata/nhe-fact-sheet.html (accessed May 23, 2017).
-
-
-
-
361
-
-
84973308480
-
Reimbursing wisely? CMS's trial of Medicare Part B Drug Payment Reform
-
Schrag, D, Reimbursing wisely? CMS's trial of Medicare Part B Drug Payment Reform. N Engl J Med 374 (2016), 2101–2105.
-
(2016)
N Engl J Med
, vol.374
, pp. 2101-2105
-
-
Schrag, D.1
-
362
-
-
84960860454
-
Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors
-
Kale, HP, Carroll, NV, Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer 122 (2016), 283–289.
-
(2016)
Cancer
, vol.122
, pp. 283-289
-
-
Kale, H.P.1
Carroll, N.V.2
-
363
-
-
84897019740
-
Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia
-
Dusetzina, SB, Winn, AN, Abel, GA, Huskamp, HA, Keating, NL, Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32 (2014), 306–311.
-
(2014)
J Clin Oncol
, vol.32
, pp. 306-311
-
-
Dusetzina, S.B.1
Winn, A.N.2
Abel, G.A.3
Huskamp, H.A.4
Keating, N.L.5
-
364
-
-
84929405050
-
The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer
-
Hershman, DL, Tsui, J, Meyer, J, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst, 106, 2014, dju319.
-
(2014)
J Natl Cancer Inst
, vol.106
, pp. dju319
-
-
Hershman, D.L.1
Tsui, J.2
Meyer, J.3
-
365
-
-
84879256683
-
Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis
-
Ramsey, S, Blough, D, Kirchhoff, A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32 (2013), 1143–1152.
-
(2013)
Health Aff (Millwood)
, vol.32
, pp. 1143-1152
-
-
Ramsey, S.1
Blough, D.2
Kirchhoff, A.3
-
366
-
-
68949112230
-
American Society of Clinical Oncology guidance statement: the cost of cancer care
-
Meropol, NJ, Schrag, D, Smith, TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 27 (2009), 3868–3874.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3868-3874
-
-
Meropol, N.J.1
Schrag, D.2
Smith, T.J.3
-
367
-
-
79952139727
-
American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer
-
Peppercorn, JM, Smith, TJ, Helft, PR, et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 29 (2011), 755–760.
-
(2011)
J Clin Oncol
, vol.29
, pp. 755-760
-
-
Peppercorn, J.M.1
Smith, T.J.2
Helft, P.R.3
-
368
-
-
85011954091
-
Validity and reliability of value assessment frameworks for new cancer drugs
-
Bentley, TG, Cohen, JT, Elkin, EB, et al. Validity and reliability of value assessment frameworks for new cancer drugs. Value Health 20 (2017), 200–205.
-
(2017)
Value Health
, vol.20
, pp. 200-205
-
-
Bentley, T.G.1
Cohen, J.T.2
Elkin, E.B.3
-
369
-
-
84925300583
-
Medicare innovation center oncology care model: a toe in the water when a plunge is needed
-
Polite, BN, Miller, HD, Medicare innovation center oncology care model: a toe in the water when a plunge is needed. J Oncol Pract 11 (2015), 117–119.
-
(2015)
J Oncol Pract
, vol.11
, pp. 117-119
-
-
Polite, B.N.1
Miller, H.D.2
-
370
-
-
85014574234
-
Financial toxicity and societal costs of cancer care: distinct problems require distinct solutions
-
Peppercorn, J, Financial toxicity and societal costs of cancer care: distinct problems require distinct solutions. Oncologist 22 (2017), 123–125.
-
(2017)
Oncologist
, vol.22
, pp. 123-125
-
-
Peppercorn, J.1
-
371
-
-
3543094440
-
Racial and ethnic disparities in health care. A position paper of the American College of Physicians
-
American College of Physicians. Racial and ethnic disparities in health care. A position paper of the American College of Physicians. Ann Intern Med 141 (2004), 226–232.
-
(2004)
Ann Intern Med
, vol.141
, pp. 226-232
-
-
-
372
-
-
0004103896
-
-
National Academy of Sciences Washington, DC
-
Hanes, MA, Smedley, BD, The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved, 1999, National Academy of Sciences, Washington, DC.
-
(1999)
The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved
-
-
Hanes, M.A.1
Smedley, B.D.2
-
374
-
-
34247369412
-
Disparities in cancer care: challenges and solutions
-
Raghavan, D, Disparities in cancer care: challenges and solutions. Oncology 21 (2007), 493–506.
-
(2007)
Oncology
, vol.21
, pp. 493-506
-
-
Raghavan, D.1
-
375
-
-
84866873044
-
Recruitment of ethnic minorities into cancer clinical trials: experience from the front lines
-
Symonds, RP, Lord, K, Mitchell, AJ, Raghavan, D, Recruitment of ethnic minorities into cancer clinical trials: experience from the front lines. Brit J Cancer 107 (2012), 1017–1021.
-
(2012)
Brit J Cancer
, vol.107
, pp. 1017-1021
-
-
Symonds, R.P.1
Lord, K.2
Mitchell, A.J.3
Raghavan, D.4
-
376
-
-
33646576857
-
Between and within: international perspectives on cancer and health disparities
-
Jones, LA, Chilton, JA, Hajek, RA, Iammarino, NK, Laufman, L, Between and within: international perspectives on cancer and health disparities. J Clin Oncol 24 (2006), 2204–2208.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2204-2208
-
-
Jones, L.A.1
Chilton, J.A.2
Hajek, R.A.3
Iammarino, N.K.4
Laufman, L.5
-
377
-
-
80051580618
-
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths
-
Siegel, R, Ward, E, Brawley, O, Jemal, A, Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61 (2011), 212–236.
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 212-236
-
-
Siegel, R.1
Ward, E.2
Brawley, O.3
Jemal, A.4
-
378
-
-
0030587798
-
The medicalization of race: scientific legitimization of a flawed social construct
-
Witzig, R, The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med 125 (1996), 675–679.
-
(1996)
Ann Intern Med
, vol.125
, pp. 675-679
-
-
Witzig, R.1
-
379
-
-
0037147189
-
Genetic structure of human populations
-
Rosenberg, NA, Pritchard, JK, Weber, JL, et al. Genetic structure of human populations. Science 298 (2002), 2381–2385.
-
(2002)
Science
, vol.298
, pp. 2381-2385
-
-
Rosenberg, N.A.1
Pritchard, J.K.2
Weber, J.L.3
-
380
-
-
33646545050
-
Genetics, epidemiology, and cancer disparities: is it black and white?
-
Rebbeck, TR, Halbert, CH, Sankar, P, Genetics, epidemiology, and cancer disparities: is it black and white?. J Clin Oncol 24 (2006), 2164–2169.
-
(2006)
J Clin Oncol
, vol.24
, pp. 2164-2169
-
-
Rebbeck, T.R.1
Halbert, C.H.2
Sankar, P.3
-
381
-
-
85046525671
-
From the Surgeon General: eliminating global cancer disparities
-
Satcher, D, From the Surgeon General: eliminating global cancer disparities. JAMA, 284, 2000, 2864.
-
(2000)
JAMA
, vol.284
, pp. 2864
-
-
Satcher, D.1
-
382
-
-
26944473246
-
Annual report to the nation on the status of cancer, 1975–2002, featuring population based trends in cancer treatment
-
Edwards, BK, Brown, ML, Wingo, PA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population based trends in cancer treatment. J Natl Cancer Inst 97 (2005), 1407–1427.
-
(2005)
J Natl Cancer Inst
, vol.97
, pp. 1407-1427
-
-
Edwards, B.K.1
Brown, M.L.2
Wingo, P.A.3
-
383
-
-
84954400636
-
Cancer statistics, 2017
-
Siegel, RL, Miller, KD, Jemal, A, Cancer statistics, 2017. CA Cancer J Clin 67 (2017), 7–30.
-
(2017)
CA Cancer J Clin
, vol.67
, pp. 7-30
-
-
Siegel, R.L.1
Miller, K.D.2
Jemal, A.3
-
384
-
-
84865313587
-
Survival disparities by Medicaid status: an analysis of 8 cancers
-
Koroukian, SM, Bakaki, P, Raghavan, D, Survival disparities by Medicaid status: an analysis of 8 cancers. Cancer 118 (2012), 4271–4279.
-
(2012)
Cancer
, vol.118
, pp. 4271-4279
-
-
Koroukian, S.M.1
Bakaki, P.2
Raghavan, D.3
-
385
-
-
34748922923
-
Cancer mortality in the United States by education level and race
-
Albano, JD, Ward, E, Jemal, A, et al. Cancer mortality in the United States by education level and race. J Natl Cancer Inst 99 (2007), 1384–1394.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 1384-1394
-
-
Albano, J.D.1
Ward, E.2
Jemal, A.3
-
386
-
-
85042183563
-
CMS wants to remodel cancer payment, care
-
Reinke, T, CMS wants to remodel cancer payment, care. Manag Care 25 (2016), 12–15.
-
(2016)
Manag Care
, vol.25
, pp. 12-15
-
-
Reinke, T.1
-
387
-
-
84863195517
-
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology
-
Schnipper, LE, Smith, TJ, Raghavan, D, et al. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 30 (2012), 1715–1724.
-
(2012)
J Clin Oncol
, vol.30
, pp. 1715-1724
-
-
Schnipper, L.E.1
Smith, T.J.2
Raghavan, D.3
-
388
-
-
84920920021
-
Tumor marker usage and medical care costs among older early-stage breast cancer survivors
-
Ramsey, SD, Henry, NL, Gralow, JR, et al. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol 33 (2015), 149–155.
-
(2015)
J Clin Oncol
, vol.33
, pp. 149-155
-
-
Ramsey, S.D.1
Henry, N.L.2
Gralow, J.R.3
-
389
-
-
84919359545
-
Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013
-
Bekelman, JE, Sylwestrzak, G, Barron, J, et al. Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008–2013. JAMA 312 (2014), 2542–2550.
-
(2014)
JAMA
, vol.312
, pp. 2542-2550
-
-
Bekelman, J.E.1
Sylwestrzak, G.2
Barron, J.3
-
390
-
-
84920926642
-
The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343
-
Palta, M, Palta, P, Bhavsar, NA, Horton, JK, Blitzblau, RC, The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of Cancer and Leukemia Group B 9343. Cancer 121 (2015), 188–193.
-
(2015)
Cancer
, vol.121
, pp. 188-193
-
-
Palta, M.1
Palta, P.2
Bhavsar, N.A.3
Horton, J.K.4
Blitzblau, R.C.5
-
391
-
-
84894067849
-
Ethical considerations for the clinical oncologist in an era of oncology drug shortages
-
Jagsi, R, Spence, R, Rathmell, WK, et al. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Oncologist 19 (2014), 186–192.
-
(2014)
Oncologist
, vol.19
, pp. 186-192
-
-
Jagsi, R.1
Spence, R.2
Rathmell, W.K.3
-
392
-
-
85021771331
-
Patient financial assistance programs: a path to affordability or a barrier to accessible cancer care?
-
Zafar, SY, Peppercorn, JM, Patient financial assistance programs: a path to affordability or a barrier to accessible cancer care?. J Clin Oncol 35 (2017), 2113–2116.
-
(2017)
J Clin Oncol
, vol.35
, pp. 2113-2116
-
-
Zafar, S.Y.1
Peppercorn, J.M.2
-
393
-
-
0142058269
-
Cancer prevention in underserved African American communities: barriers and effective strategies. A review of the literature
-
Wolff, M, Bates, T, Beck, B, et al. Cancer prevention in underserved African American communities: barriers and effective strategies. A review of the literature. WMJ 102 (2003), 36–40.
-
(2003)
WMJ
, vol.102
, pp. 36-40
-
-
Wolff, M.1
Bates, T.2
Beck, B.3
-
394
-
-
18044403228
-
Recruitment and retention of minority women in cancer screening, prevention, and treatment trials
-
Brown, DR, Fouad, MN, Basen-Engquist, K, et al. Recruitment and retention of minority women in cancer screening, prevention, and treatment trials. Ann Epidemiol 10 (2000), S13–S21.
-
(2000)
Ann Epidemiol
, vol.10
, pp. S13-S21
-
-
Brown, D.R.1
Fouad, M.N.2
Basen-Engquist, K.3
-
395
-
-
0032531684
-
Prevention and control in diverse Hispanic populations: a national initiative for research and action
-
Ramirez, AG, McAlister, A, Villarreal, R, et al. Prevention and control in diverse Hispanic populations: a national initiative for research and action. Cancer 83:suppl (1998), S1825–S1829.
-
(1998)
Cancer
, vol.83
, pp. S1825-S1829
-
-
Ramirez, A.G.1
McAlister, A.2
Villarreal, R.3
-
396
-
-
16444381731
-
Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer
-
Armstrong, K, Micco, E, Carney, A, Stopfer, J, Putt, M, Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 293 (2005), 1729–1736.
-
(2005)
JAMA
, vol.293
, pp. 1729-1736
-
-
Armstrong, K.1
Micco, E.2
Carney, A.3
Stopfer, J.4
Putt, M.5
-
397
-
-
31844442247
-
Race and surgical mortality in the United States
-
Lucas, FL, Stukel, TA, Morris, AM, Siewers, AE, Birkmeyer, JD, Race and surgical mortality in the United States. Ann Surg 243 (2006), 281–286.
-
(2006)
Ann Surg
, vol.243
, pp. 281-286
-
-
Lucas, F.L.1
Stukel, T.A.2
Morris, A.M.3
Siewers, A.E.4
Birkmeyer, J.D.5
-
398
-
-
26444519200
-
Comorbidity and survival disparities among black and white patients with breast cancer
-
Tammemagi, CM, Nerenz, D, Neslund-Dudas, C, Feldkamp, C, Nathanson, D, Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294 (2005), 1765–1772.
-
(2005)
JAMA
, vol.294
, pp. 1765-1772
-
-
Tammemagi, C.M.1
Nerenz, D.2
Neslund-Dudas, C.3
Feldkamp, C.4
Nathanson, D.5
-
399
-
-
18644379692
-
Ethnic disparities in the treatment of stage I non-small cell lung cancer
-
Wisnivesky, JP, McGinn, T, Henschke, C, Hebert, P, Iannuzzi, MC, Halm, EA, Ethnic disparities in the treatment of stage I non-small cell lung cancer. Am J Respir Crit Care Med 171 (2005), 1158–1163.
-
(2005)
Am J Respir Crit Care Med
, vol.171
, pp. 1158-1163
-
-
Wisnivesky, J.P.1
McGinn, T.2
Henschke, C.3
Hebert, P.4
Iannuzzi, M.C.5
Halm, E.A.6
-
400
-
-
67649934430
-
American Society of Clinical Oncology policy statement—disparities in cancer care
-
Goss, E, Lopez, AM, Brown, CL, Wollins, DS, Brawley, OW, Raghavan, D, American Society of Clinical Oncology policy statement—disparities in cancer care. J Clin Oncol 27 (2009), 2881–2885.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2881-2885
-
-
Goss, E.1
Lopez, A.M.2
Brown, C.L.3
Wollins, D.S.4
Brawley, O.W.5
Raghavan, D.6
-
401
-
-
84978264042
-
The state of lung cancer research: a global analysis
-
Aggarwal, A, Lewison, G, Idir, S, et al. The state of lung cancer research: a global analysis. J Thorac Oncol 11 (2016), 1040–1050.
-
(2016)
J Thorac Oncol
, vol.11
, pp. 1040-1050
-
-
Aggarwal, A.1
Lewison, G.2
Idir, S.3
-
402
-
-
44349145010
-
Rescue of salivary gland function after stem cell transplantation in irradiated glands
-
Lombaert, IM, Brunsting, JF, Wierenga, PK, et al. Rescue of salivary gland function after stem cell transplantation in irradiated glands. PLoS One, 3, 2008, e2063.
-
(2008)
PLoS One
, vol.3
, pp. e2063
-
-
Lombaert, I.M.1
Brunsting, J.F.2
Wierenga, P.K.3
|